

Curriculum Vitæ

Name SCARTOZZI Mario, MD, Prof
Institution Medical Oncology, University of Cagliari
Phone +39 070 5009 3217
Mobile
Fax +39 070 5009 3215
E-mail marioscartozzi@unica.it

<https://www.linkedin.com/in/mario-scartozzi-737773274/>
Citizenship ITA
DOB/Place

Personal Assistant Mrs Tiziana Bevere,

Phone + 39 070 5109 3222
Fax + 39 070 5109 3215
E-mail segreteriaprofscartozzi@aoucagliari.it

Education

12/11/1999
Medical Oncologist (post-graduate School in Medical Oncology) **CUM LAUDE**
Università Politecnica delle MARCHE – ANCONA, Italy

26/10/1995
MD, **CUM LAUDE**
Medical School, Università Politecnica delle MARCHE - ANCONA, Italy

10/07/1989
High School Graduate
Liceo Classico Mamiani High School Pesaro, Italy

Jobs

3/11/2014 to date

Professor in Medical Oncology (Full Professor since 2017)

University of Cagliari, Italy

Head

Medical Oncology

University of Cagliari and University Hospital of Cagliari, Italy

Head DAI Obstetrics, Gynecology, Pediatrics and Oncology (2020-2024)

University Hospital, Cagliari, Italy (AOU Ca)

Head DAI Medical Specialties (since 2024)

University Hospital, Cagliari, Italy (AOU Ca)

Head

Post-Graduate School in Medical Oncology

University of Cagliari, Italy

Full Member of the Academic Commission of the PhD course in Translational Medicine

University of Cagliari, Italy

01/01/2010 – 2/11/2014

Head Translational Research Unit

Università Politecnica delle MARCHE Azienda Ospedaliero Universitaria - Ospedali Riuniti – ANCONA, Italy

01/01/2004 – 2/11/2014

Consultant Medical Oncologist, Head

Gastrointestinal Tumours Unit

Azienda Ospedaliero Universitaria - Ospedali Riuniti, ANCONA, Italy

01/01/2001 – 2/11/2014

Senior Lecturer

Postgraduate School in Medical Oncology, Università Politecnica delle MARCHE - ANCONA, Italy

10/02/2000 – 31/12/2003

Consultant Medical Oncologist

Azienda Ospedaliero Universitaria - Ospedali Riuniti, ANCONA, Italy

01/12/1999-10/02/2000

Italian Society for Cancer Research (AIRC)

Fellowship for Cancer Research (genetics of colorectal tumours)

Medical Oncology, Università Politecnica delle MARCHE –
ANCONA, Italy

10/06/1999-10/12/1999

Research Fellow

Clinical Fellow

Medical Oncology, University College London - <http://www.ucl.ac.uk/> - London, UK

Funded Research Projects

Project	Grant (euros)
Molecular Biology of Pancreatic Tumors Italian Ministry of Health	140.000
Tumour Hypoxia in rectal cancer Università Politecnica delle Marche 2004, Ancona, Italy	10.000
Pharmacogenomics and Chemotherapy CARIVERONA 2005, Italy	80.000
Pharmacogenomics in rectal cancer Università Politecnica delle Marche 2005, Italy	10.000
Molecular Biology of NETs PRIN 2005, Ministry of Education, Italy	130.000
Molecular biomarkers in GI tumours Italian Ministry of Health and Marche Region 2005	85.000
Molecular markers for cancer susceptibility, diagnosis and treatment in gastric and bladder tumours AIRC Regional Grant 2006, Italy	180.000
EGFR in colon cancer Università Politecnica delle Marche 2006, Italy	8.000
Angiogenesis in colon cancer Università Politecnica delle Marche 2009	8.000
TUMOUR ANGIOGENIC PATHWAY AS A THERAPEUTIC TARGET FOR COLORECTAL CANCER PATIENTS-AIRC 2009, Italy	100.000
Development of effective cancer therapies based on functional proteomics and cancer stem cell targeting-AIRC 5 x1000, 2010, Italy	960.000
Prospective selection of colorectal cancer patients for anti-EGFR treatment. AIRC 2011, Italy	200.000
COLORECTAL CANCER, EGFR INHIBITOR RESISTANCE, PATIENT SELECTION FOR PERSONALIZED THERAPIES-PRIN2012, Italy	210.000
Prospective selection according to LDH serum levels in advanced colorectal cancer patients receiving bevacizumab. ROCHE/GISCAD 2013, Italy	130.000

Prospective validation of a clinical and molecular selection profile in colorectal cancer patients Receiving regorafenib (Bayer, 2016)	90.000
Selection with a molecular Panel for Panitumumab Efficacy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER-PEAK) (Amgen 2016)	90.000
second-line folfiri/aflibercept in prospectively stratified, anti-EGFR resistant, metastatic colorectal cancer patients with RAS Validated wild type status (The DISTINCTIVE Study) (SANOFI/GISCAD 2017)	225.000
Bando Ministeriale Piano Operativo Salute Traiettorie 4	800.000
HUB per sviluppo di terapie avanzate personalizzate con approcci integrati che sfruttino piattaforme d'avanguardia (Ministero della Salute, 2022)	

Editorial Board Memberships

Titolo	From	to
Editorial Board Annals of Oncology	2014	date
Editorial Board Manuale di Medicina Oncologica, Casa Editrice Elsevier	2012	date
Editorial Board Journal of Molecular Biomarkers & Diagnosis	2010	date
Editorial Board BioMed Research International	2014	date
Academic Editor Medicine	2014	date
Italian Society for Medical Oncology (AIOM) Guidelines Gastric Cancer	2011	date
Italian Society for Medical Oncology (AIOM) Guidelines Hepatocellular Carcinoma	2013	date

Awards and Recognitions

- Best Young Researcher Award, Premio Giovane Ricercatore Università degli Studi di Ancona, Italy 1999
- Oral presentation National Congress of Medical Oncology, Congresso Nazionale Oncologia Medica, Italy 2003
(Loss of hMLH1 expression correlates with improved survival in stage IIIIV ovarian cancer patients)
- Best Poster Award European Society for Medical Oncology (ESMO) Annual Meeting 2004
(Epidermal growth factor receptor (EGFR) status in primary colorectal tumours does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted antibodies
- Oral Presentation COMU 2005
(Mismatch Repair System (MMR) status correlates with response and survival in non small cell lung cancer (NSCLC) patients).
- Oral Presentation Gastrointestinal Cancers Symposium 2006, San Francisco, USA
(Epidermal Growth Factor Receptor (EGFR) downstream signaling pathway in primary colorectal tumors and related metastatic sites: Optimizing EGFR targeted treatment options)
- Oral Presentation National Congress of Medical Oncology Congresso Nazionale Associazione Italiana di Oncologia Medica (AIOM) 2006 (LYMPHATIC, BLOOD VESSEL AND PERINEURAL INVASION (LBVI/PNI) IDENTIFIES EARLY STAGE HIGH RISK RADICALLY RESECTED GASTRIC CANCER PATIENTS)
- Oral Presentation, National Congress of Medical Oncology Congresso Nazionale Associazione Italiana di Oncologia Medica (AIOM) 2007 (Nuclear factor-kb (NF-KB) tumor expression predicts response and survival in

irinotecanrefractory metastatic colorectal cancer patients treated with cetuximab-irinotecan therapy)

-Best Young Researcher Award Fondazione Berlucci 2009, Italy

-Oral Presentation, National Congress of Medical Oncology, Congresso Nazionale Associazione Italiana di oncologia Medica (AIOM) 2010 (THE ROLE OF HER-3 EXPRESSION IN THE PREDICTION OF CLINICAL OUTCOME FOR ADVANCED COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN-CETUXIMAB)

-Oral Presentation ECCO-ESMO-ESTRO Annual Meeting 2011, Stockholm, Sweden
(Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab)

-Oral presentation National Congress of Medical Oncology Congresso Nazionale Associazione Italiana di Oncologia Medica (AIOM) 2011.
(THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTORS GENOTYPING IN GUIDING THE METASTATIC PROCESS IN RADICALLY RESECTED GASTRIC CANCER PATIENTS).

Reviewer for:

Journal of Clinical Oncology, Lancet Oncology, Lancet, GUT, Annals of
Oncology, Pharmacogenomics, Pharmacogenomics Journal, British Journal of
Cancer, European Journal of Cancer, International Journal of Cancer, CROH,
Cancer Treatment Reviews, PLOSone, BMC Cancer, Cancer Letters, Tumori

Publications (indexed, full text only)

1. Pinto C, Lonardi S, Maiello E, Martinelli E, Prisciandaro M, Salvatore L, Sartore-Bianchi A, Scartozzi M, Aprile G, Cremolini C, Sobrero A. Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion. *Front Oncol.* 2025 Jan 22;14:1502185. doi: 10.3389/fonc.2024.1502185. PMID: 39911824; PMCID:
2. Milella M, Orsi G, di Marco M, Salvatore L, Procaccio L, Noventa S, Bozzarelli S, Garajova I, Vasile E, Giordano G, Macchini M, Cavaliere A, Gaule M, Bergamo F, Chiaravalli M, Palloni A, Carloni R, Bittoni A, Niger M, Rapposelli IG, Rodriquenz MG, Scartozzi M, Mosconi S, Giommoni E, Bernardini I, Paratore C, Spallanzani A, Bencardino K, Forti L, Tamburini E, Lonardi S, Scarpa A, Cascinu S, Tortora G, Sperduti I, Reni M. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. *Cancer Med.* 2025 Feb;14(3):e70364. doi: 10.1002/cam4.70364.
3. Vetere G, Germani MM, Antoniotti C, Salvatore L, Pietrantonio F, Lonardi S, Bensi M, Ghelardi F, Calegari MA, Intini R, Minelli A, Sullo FG, Boccaccio C, Taravella A, Puccini A, Lavacchi D, Noto L, Salati M, Scartozzi M, Cremolini C. Prognostic impact of depth of response and early tumour shrinkage in patients with *BRAF*^{V600E}-mutated metastatic colorectal cancer treated with targeted therapy. *Ther Adv Med Oncol.* 2025 Jan 7;17:17588359241299975. doi: 10.1177/17588359241299975. PMID: 39776534; PMCID: PMC11705328.
4. Bertaglia V, Petrelli F, Dottorini L, Carnio S, Morelli AM, Nepote A, Maccioni A, Scartozzi M, Solinas C, Novello S. Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis. *Semin Oncol.* 2024 Dec 31:S0093-7754(24)00064-2. doi: 10.1053/j.seminoncol.2024.11.001. Epub ahead of print. PMID: 39743384.
5. Serra R, Giunta EF, Schepisi G, Brighi N, Montanari D, Lolli C, Bleve S, Piras M, Palmieri G, Scartozzi M, Paliogiannis P, De Giorgi U. An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer. *Expert Rev Anticancer Ther.* 2024 Dec;24(12):1221-1227. doi: 10.1080/14737140.2024.2445152. Epub 2024 Dec 25.
6. Faa G, Frascini M, Didaci L, Saba L, Scartozzi M, Orvieto E, Rugge M. "Artificial histology" in colonic Neoplasia: A critical approach. *Dig Liver Dis.* 2024 Nov 29:S1590-8658(24)01089-2. doi: 10.1016/j.dld.2024.11.001. Epub ahead of print. PMID: 39616091.
7. Pretta A, Ziranu P, Perissinotto E, Ghelardi F, Marmorino F, Giampieri R, Puci M, De Grandis MC, Lai E, Nasca V, Ciraci P, Puzzone M, Cerma K, Sciortino C, Taravella A, Pretta G, Giuliani L, Damonte C, Pusceddu V, Sotgiu G, Berardi R, Lonardi S, Bergamo F, Pietrantonio F, Cremolini C, Scartozzi M. Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon. *Br J Cancer.* 2025 Feb;132(2):188-194. doi: 10.1038/s41416-024-02902-5. Epub 2024 Nov 27. PMID: 39604610;
8. Filippi R, Brandi G, Casadei-Gardini A, Leone F, Silvestris N, Satolli MA, Salani F, Sperti E, Lutrino SE, Aprile G, Santini D, Scartozzi M, Faloppi L, Palloni A, Deserti M, Tavolari S, Rimini M, Brunetti O, Spadi R, Ilaria D, Di Maio M. Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance. *Cancer Invest.* 2025 Jan;43(1):59-69. doi: 10.1080/07357907.2024.2432013. Epub 2024 Nov 27. PMID: 39601419.
9. Lo Prinzi F, Salani F, Rimini M, Rizzato MD, Antonuzzo L, Camera S, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Melo Alvim C, Roque R
10. Fornaro L, De Rosa A, Lavacchi D, Rossari F, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Viola MG, Silvestro L, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Ahcene Djaballah S, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real life worldwide population. *Oncologist.* 2024 Oct 19:oyae256. doi: 10.1093/oncolo/oyae256. Epub ahead of print. PMID: 39427227.
11. Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto

- N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Mascia L, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Rimini M. Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study. *Oncology*. 2024 Oct 11:1-13. doi: 10.1159/000541018. Epub ahead of print. PMID: 39396495.
12. 11: Madeddu C, Gramignano G, Lai E, Pinna G, Tanca L, Cherchi MC, Floris C, Farci D, Pretta A, Scartozzi M, Macciò A. Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors. *ESMO Open*. 2024 Oct;9(10):103738. doi: 10.1016/j.esmoop.2024.103738. Epub 2024 Oct 10. PMID: 39389003; PMCID: PMC11693429.
 13. 12: Cimbro E, Dessi M, Ziranu P, Madeddu C, Atzori F, Lai E, Pretta A, Mariani S, Donisi C, Spanu D, Pozzari M, Murgia S, Saba G, Codipietro C, Palmas E, Sanna G, Semonella F, Sardo S, Finco G, Scartozzi M. Early taxane exposure and neurotoxicity in breast cancer patients. *Support Care Cancer*. 2024 Oct 8;32(10):709. doi: 10.1007/s00520-024-08908-2. PMID: 39375221; PMCID: PMC11458724.
 14. 13: Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Camera S, Stefanini B, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M. Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study. *Liver Cancer*. 2024 Apr 10;13(5):522-536. doi: 10.1159/000537915. PMID: 39296620;
 15. 14: Carconi C, Bosi C, Scartozzi M, Cergnul M, Cinausero M, Faloppi L, Garajova I, Lonardi S, Pecora I, Pisanu L, Spadi R, Spallanzani A, Peretti U, Macchini M, Orsi G, Reni M. A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants. *Pancreatology*. 2024 Nov;24(7):1066-1072. doi: 10.1016/j.pan.2024.09.006. Epub 2024 Sep 12. PMID: 39277480.
 16. 15: Rimini M, Montes M, Amadeo E, Vitiello F, Kudo M, Tada T, Suda G, Shimose S, Lonardi S, Finkelmeier F, Salani F, Antonuzzo L, Marra F, Iavarone M, Cabibbo G, Foschi FG, Silletta M, Sacco R, Rapposelli IG, Scartozzi M, Nicoletta P, Aldrighetti L, Persano M, Camera S, Rossari F, Foti S, Kumada T, Hiraoka A, Iwamoto H, Rizzato MD, Himmelsbach V, Masi G, Corradi M, Celsa C, Fabio C, Frassinetti GL, Cascinu S, Casadei-Gardini A, Presa J. Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab. *Sci Rep*. 2024 Aug 30;14(1):20200. doi: 10.1038/s41598-024-70928-z. PMID: 39215078;
 17. 16: Frascini M, Castagnola M, Barberini L, Sanfilippo R, Coghe F, Didaci L, Cau R, Frongia C, Scartozzi M, Saba L, Faa G. An Unsupervised Learning Tool for Plaque Tissue Characterization in Histopathological Images. *Sensors (Basel)*. 2024 Aug 20;24(16):5383. doi: 10.3390/s24165383.
 18. Faa G, Coghe F, Pretta A, Castagnola M, Van Eyken P, Saba L, Scartozzi M, Frascini M. Artificial Intelligence Models for the Detection of Microsatellite Instability from Whole-Slide Imaging of Colorectal Cancer. *Diagnostics (Basel)*. 2024 Jul 25;14(15):1605. doi: 10.3390/diagnostics14151605. PMID: 39125481; PMCID: PMC11311951.
 19. Margonis GA, Wang JJ, Boerner T, Moretto R, Buettner S, Andreatos N, Gagnière J, Wagner D, Løes IM, Bergamo F, Pietrantonio F, Scartozzi M, Spallanzani A, Vincenzi B, Antoniou E, Pikoulis E, Sartore-Bianchi A, Stasinou G, Sasaki K, Pawlik TM, Orlandi A, Pella N, Fitschek F, Kaczirek K, Dupré A, Pozios I, Beyer K, Kornprat P, Aucejo FN, Burkhart R, Weiss MJ, Lønning PE, Poultsides G, Cremolini C, Kreis ME, D'Angelica M. Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study. *Br J Surg*. 2024 Jul 2;111(7):znae176. doi: 10.1093/bjs/znae176. PMID: 39051667; PMCID: PMC11270119.

20. Rimini M, Fornaro L, Rizzato MD, Antonuzzo L, Rossari F, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Chon HJ, Braconi C, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofers L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Salani F, De Rosa A, Lavacchi D, Foti S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population. *Eur J Cancer*. 2024 Sep;208:114199. doi: 10.1016/j.ejca.2024.114199. Epub 2024 Jun 30. PMID: 39002348.
21. Pressiani T, Balsano R, Giordano L, Milella M, Bergamo F, Bozzarelli S, Noventa S, Ferrari D, Scartozzi M, Parra HS, Auriemma A, Soldà C, Zaniboni A, Zecchetto C, Rizzato MD, Rimassa L, Santoro A. Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer. *Eur J Cancer*. 2024 Aug;207:114196. doi: 10.1016/j.ejca.2024.114196. Epub 2024 Jun 29. PMID: 38954899.
22. Rimini M, Masi G, Lonardi S, Nichetti F, Pressiani T, Lavacchi D, Jessica L, Giordano G, Scartozzi M, Tamburini E, Pastorino A, Rapposelli IG, Daniele B, Martinelli E, Garajova I, Aprile G, Schirripa M, Formica V, Salani F, Winchler C, Bergamo F, Balsano R, Gusmaroli E, Lorenzo A, Landriscina M, Pretta A, Toma I, Pirrone C, Diana A, Leone F, Brunetti O, Brandi G, Garattini SK, Satolli MA, Rossari F, Fornaro L, Niger M, Zanuso V, De Rosa A, Ratti F, Aldrighetti L, De Braud F, Foti S, Rizzato MD, Vivaldi C, Stefano C, Rimassa L, Antonuzzo L, Casadei-Gardini A. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. *Target Oncol*. 2024 May;19(3):359-370. doi: 10.1007/s11523-024-01060-1. Epub 2024 May 1. PMID: 38691295.
23. Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab. *Target Oncol*. 2024 Jul;19(4):645-659. doi: 10.1007/s11523-024-01061-0. Epub 2024 Apr 30. PMID: 38689194; PMCID: PMC11230956.
24. Ziranu P, Pretta A, Aimola V, Cau F, Mariani S, D'Agata AP, Codipietro C, Rizzo D, Dell'Utri V, Sanna G, Moleda G, Cadoni A, Lai E, Puzzone M, Pusceddu V, Castagnola M, Scartozzi M, Faa G. CD44: A New Prognostic Marker in Colorectal Cancer? *Cancers (Basel)*. 2024 Apr 19;16(8):1569. doi: 10.3390/cancers16081569. PMID: 38672650; PMCID: PMC11048923.
25. Corrias G, Lai E, Ziranu P, Mariani S, Donisi C, Liscia N, Saba G, Pretta A, Persano M, Fanni D, Spanu D, Balconi F, Loi F, Deidda S, Restivo A, Pusceddu V, Puzzone M, Solinas C, Massa E, Madeddu C, Gerosa C, Zorcolo L, Faa G, Saba L, Scartozzi M. Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging. *Cancers (Basel)*. 2024 Mar 30;16(7):1364. doi: 10.3390/cancers16071364. PMID: 38611042; PMCID: PMC11011199.
26. Tommasi C, Airò G, Praticò F, Testi I, Corianò M, Pellegrino B, Denaro N, Demurtas L, Dessì M, Murgia S, Mura G, Wekking D, Scartozzi M, Musolino A, Solinas C. Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies. *J Clin Med*. 2024 Mar 24;13(7):1873. doi: 10.3390/jcm13071873. PMID: 38610638; PMCID: PMC11012464.
27. Donisi C, Pretta A, Pusceddu V, Ziranu P, Lai E, Puzzone M, Mariani S, Massa E, Madeddu C, Scartozzi M. Immunotherapy and Cancer: The Multi-Omics Perspective. *Int J Mol Sci*. 2024 Mar 21;25(6):3563. doi: 10.3390/ijms25063563. PMID: 38542536; PMCID: PMC10971308.
28. Rimini M, Loi E, Rizzato MD, Pressiani T, Vivaldi C, Gusmaroli E, Antonuzzo L, Martinelli E, Garajova I, Giordano G, Lucchetti J, Schirripa M, Cornara N, Rossari F, Vitiello F, Amadeo E, Persano M, Piva VM, Balsano R, Salani F, Pircher C, Cascinu S, Niger M, Fornaro L, Rimassa L, Lonardi S, Scartozzi M, Zavattari P, Casadei-Gardini A. Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab. *Target Oncol*. 2024 Feb 12. doi: 10.1007/s11523-024-01032-5. Epub ahead of print. PMID: 38345693.

29. Speranza D, Sapuppo E, Aprile G, Auriemma A, Bergamo F, Bianco R, Bordonaro R, Brandi G, Brunetti O, Carnaghi C, Ciliberto D, Cinieri S, Corallo S, De Vita F, Di Donato S, Ferrà F, Fornaro L, Barucca V, Giommoni E, Lotesoriere C, Luchini C, Masini C, Niger M, Pisconti S, Rapposelli IG, Rimassa L, Rognone C, Rodriquenz MG, Corsini LR, Santin D, Scarpa A, Scartozzi M, Soto Parra H, Tonin G, Tortora G, Tralongo P, Silvestris N. The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO). *Tumori*. 2024 Feb 7:3008916231222761. doi: 10.1177/03008916231222761. Epub ahead of print. PMID: 38326240.
30. Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Salani F, Marseglia M, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Lonardi S, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma. *Target Oncol*. 2024 Jan;19(1):29-39. doi: 10.1007/s11523-023-01029-6. Epub 2024 Jan 22. PMID: 38252195.
31. Wekking D, Lambertini M, Dessì M, Denaro N, Bardanzellu F, Garrone O, Scartozzi M, Solinas C. CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety. *Semin Oncol*. 2024 Jan 13:S0093-7754(24)00002-2. doi: 10.1053/j.seminoncol.2024.01.002. Epub ahead of print. PMID: 38245458.
32. Massa E, Lai E, Donisi C, Scartozzi M, Orgiano L, Mulas O, Pretta A, Caocci G, Carta MG. Understanding the User's Point of View: When the Doctor Gets Sick with Cancer and Seeks Help. *Clin Pract Epidemiol Ment Health*. 2023 Oct 13;19:e17450179241325. doi: 10.2174/0117450179241325231011070735. PMID: 38164454; PMCID: PMC10758133.
33. Martella S, Lucas M, Porcu M, Perra L, Denaro N, Pretta A, Deias G, Willard- Gallo K, Parra HS, Saba L, Scartozzi M, Wekking D, Kok M, Aiello MM, Solinas C. Primary adrenal insufficiency induced by immune checkpoint inhibitors: Biological, clinical, and radiological aspects. *Semin Oncol*. 2023 Dec 6:S0093-7754(23)00083-0. doi: 10.1053/j.seminoncol.2023.11.003. Epub ahead of print. PMID: 38151399.
34. Denaro N, Nazzaro G, Murgia G, Scarfi F, Cauchi C, Carrera CG, Cattaneo A, Solinas C, Scartozzi M, Marzano AV, Garrone O, Passoni E. A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review. *Int J Mol Sci*. 2023 Dec 16;24(24):17540. doi: 10.3390/ijms242417540. PMID: 38139369; PMCID: PMC10743950.
35. Wekking D, Senevirathne TH, Pearce JL, Aiello M, Scartozzi M, Lambertini M, De Silva P, Solinas C. The impact of COVID-19 on cancer patients. *Cytokine Growth Factor Rev*. 2023 Nov 30:S1359-6101(23)00087-4. doi: 10.1016/j.cytogfr.2023.11.004. Epub ahead of print. PMID: 38103990.
36. Martella S, Aiello MM, Bertaglia V, Cau R, Denaro N, Cadoni A, Novello S, Scartozzi M, Novello G, Soto Parra HJ, Saba L, Solinas C, Porcu M. Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors. *Target Oncol*. 2024 Jan;19(1):13-28. doi: 10.1007/s11523-023-01017-w. Epub 2023 Dec 8. PMID: 38063957.
37. Floris M, Angioi A, Lepori N, Mascia G, Trevisani F, Boero M, Scartozzi M, Cabiddu G, Pani A. [An Integrated Multidisciplinary Approach to the Care of Renal Cancer Patients Undergoing Nephrectomy]. *G Ital Nefrol*. 2023 Oct 3;40(Suppl 81):2023-S81. Italian. PMID: 38007831.
38. Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Burgio V, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M. α -FA τ E: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. *Int J Cancer*. 2024 Mar 15;154(6):1043-1056. doi: 10.1002/ijc.34799. Epub 2023 Nov 23. PMID: 37994647.
39. Wekking D, Porcu M, Pellegrino B, Lai E, Mura G, Denaro N, Saba L, Musolino A, Scartozzi M, Solinas C. Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and

- effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients. *ESMO Open*. 2023 Dec;8(6):102043. doi: 10.1016/j.esmoop.2023.102043. Epub 2023 Nov 10. PMID: 37951130; PMCID: PMC10679891.
40. Wekking D, Leoni VP, Lambertini M, Dessi M, Pretta A, Cadoni A, Atzori L, Scartozzi M, Solinas C. CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects. *Cytokine Growth Factor Rev*. 2023 Oct 5:S1359-6101(23)00075-8. doi: 10.1016/j.cytogfr.2023.10.001. Epub ahead of print. PMID: 37838584.
 41. Sardo S, Varrassi G, Scartozzi M, Pace MC, Schweiger V, Tamburin S, Musu M, Finco G. Exploring Outcome Priorities and Real-Life Management of Chemotherapy Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members. *J Pain Res*. 2023 Sep 25;16:3227-3238. doi:10.2147/JPR.S414389. PMID: 37790191; PMCID: PMC10542526.
 42. Denaro N, Passoni E, Indini A, Nazzaro G, Beltramini GA, Benzecry V, Colombo G, Cauchi C, Solinas C, Scartozzi M, Marzano AV, Garrone O. Cemiplimab in Ultra- Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center. *Vaccines (Basel)*. 2023 Sep 18;11(9):1500. doi: 10.3390/vaccines11091500. PMID: 37766176; PMCID: PMC10534594.
 43. Pretta A, Zirano P, Giampieri R, Pinna G, Randon G, Donisi C, Ravarino A, Loi F, Deias G, Palmas E, Pretta G, Morano F, Semonella F, Mariani S, Deidda MA, Pusceddu V, Puzzone M, Lai E, Solinas C, Restivo A, Zorcolo L, Barbara R, Berardi R, Faa G, Pietrantonio F, Scartozzi M. Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy. *Br J Cancer*. 2023 Nov;129(10):1619-1624. doi: 10.1038/s41416-023-02444-2. Epub 2023 Sep 25. PMID: 37749283; PMCID: PMC10646038.
 44. Wekking D, Pretta A, Martella S, D'Agata AP, Joeun Choe J, Denaro N, Solina C, Scartozzi M. Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas. *Heliyon*. 2023 Aug 27;9(9):e19541. doi: 10.1016/j.heliyon.2023.e19541. PMID: 37681152; PMCID: PMC10481293.
 45. Zirano P, Ferrari PA, Guerrera F, Bertoglio P, Tamburrini A, Pretta A, Lyberis P, Grimaldi G, Lai E, Santoru M, Bardanzellu F, Riva L, Balconi F, Della Beffa E, Dubois M, Pinna-Susnik M, Donisi C, Capozzi E, Pusceddu V, Murenu A, Puzzone M, Mathieu F, Sarais S, Alzetani A, Luzzi L, Solli P, Paladini P, Ruffini E, Cherchi R, Scartozzi M. Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score. *Lung Cancer*. 2023 Oct;184:107342. doi: 10.1016/j.lungcan.2023.107342. Epub 2023 Aug 9. PMID: 37573705.
 46. Lonardi S, Rasola C, Lobefaro R, Rossini D, Formica V, Scartozzi M, Frassinetti GL, Boscolo G, Cinieri S, Di Donato S, Pella N, Bergamo F, Raimondi A, Arnoldi E, Antonuzzo L, Granetto C, Zustovich F, Ronzoni M, Leo S, Morano F, Loupakis F, Buggin F, Zagonel V, Fassan M, Cremolini C, Boni L, Pietrantonio F; GONO Foundation Investigators. Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation. *J Clin Oncol*. 2023 Dec 1;41(34):5263-5273. doi: 10.1200/JCO.23.00506. Epub 2023 Aug 3. PMID: 37535876.
 47. Rimini M, Burgio V, Antonuzzo L, Rimassa L, Oneda E, Soldà C, Cito P, Nasti G, Lavacchi D, Zanuso V, Rizzato MD, Zaniboni A, Ottaiano A, Persano M, Cornara N, Scartozzi M, Cascinu S, Casadei-Gardini A. Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic- cholangiocarcinoma: an Italian real-world experience. *Ther Adv Med Oncol*. 2023 Jul 12;15:17588359231171574. doi: 10.1177/17588359231171574. PMID: 37457302; PMCID: PMC10345913.
 48. Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, Lucchetti J, Giordano G, Pretta A, Tamburini E, Pirrone C, Rapposelli IG, Diana A, Martinelli E, Garajová I, Simionato F, Schirripa M, Formica V, Vivaldi C, Caliman E, Rizzato MD, Zanuso V, Nichetti F, Angotti L, Landriscina M, Scartozzi M, Ramundo M, Pastorino A, Daniele B, Cornara N, Persano M, Gusmaroli E, Cerantola R, Salani F, Ratti F, Aldrighetti L, Cascinu S, Rimassa L, Antonuzzo L, Casadei-Gardini A. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data. *Liver Int*. 2023 Aug;43(8):1803-1812. doi: 10.1111/liv.15641. PMID: 37452505.
 49. Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Niizeki T, Montes M, Vivaldi C, Soldà C, Stefanini B, Hiraoka A, Sho T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa

- N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Campani C, Amadeo E, Rossari F, Burgio V, Cascinu S, Scartozzi M, Casadei-Gardini A. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. *Eur J Cancer*. 2023 Aug;189:112933. doi: 10.1016/j.ejca.2023.05.021. Epub 2023 Jun 1. PMID: 37385069.
50. Malapelle U, Angerilli V, Pepe F, Fontanini G, Lonardi S, Scartozzi M, Memeo L, Pruneri G, Marchetti A, Perrone G, Fassan M. The ideal reporting of *RAS* testing in colorectal adenocarcinoma: a pathologists' perspective. *Pathologica*. 2023 Jun 14;115(3):137–47. doi: 10.32074/1591-951X-895. Epub ahead of print. PMID: 37314870; PMCID: PMC10462993.
 51. Procaccio L, Merz V, Fasano M, Vaccaro V, Giommoni E, Pretta A, Noventa S, Satolli MA, Giordano G, Zichi C, Pinto C, Zecchetto C, Barsotti G, De Vita F, Milella M, Antonuzzo L, Scartozzi M, Zaniboni A, Spadi R, Casalino S, Bergamo F, De Toni C, Melisi D, Lonardi S. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. *Cancer Med*. 2023 Jul;12(13):14337-14345. Doi 10.1002/cam4.6111. Epub 2023 Jun 6. PMID: 37278395; PMCID: PMC10358242.
 52. Napolitano S, De Falco V, Martini G, Ciardiello D, Martinelli E, Della Corte CM, Esposito L, Famiglietti V, Di Liello A, Avallone A, Cardone C, De Stefano A, Montesarchio V, Zampino MG, Bordonaro R, Scartozzi M, Santini D, Di Maio M, De Vita F, Altucci L, Marrone F, Ciardiello F, Troiani T. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. *JAMA Oncol*. 2023 Jul 1;9(7):966-970. doi: 10.1001/jamaoncol.2023.0655. PMID: 37200022; PMCID: PMC10196928.
 53. Casadei-Gardini A, Leone F, Brandi G, Scartozzi M, Silvestris N, Santini D, Faloppi L, Aglietta M, Satolli MA, Rizzo A, Lonardi S, Aprile G, Fornaro L. Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy. *Front Oncol*. 2023 Apr 5;13:1128930. doi: 10.3389/fonc.2023.1128930. PMID: 37091141; PMCID: PMC10113474.
 54. Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Salani F, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Schirripa M, Montes M, Vivaldi C, Soldà C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. *J Cancer Res Clin Oncol*. 2023 Aug;149(10):7565-7577. doi: 10.1007/s00432-023-04678-2. Epub 2023 Mar 28. PMID: 36976353.
 55. Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Pressiani T, Piscaglia F, Kumada T, Rimassa L, Scartozzi M, Cascinu S, Casadei-Gardini A; HCC COLLABORATIVE GROUP. Identification of Atezolizumab Plus Bevacizumab Prognostic Index *via* Recursive Partitioning Analysis in HCC: The ABE Index. *Anticancer Res*. 2023 Apr;43(4):1599-1610. doi: 10.21873/anticancer.16310. Erratum in: *Anticancer Res*. 2023 May;43(5):2381. PMID: 36974779.
 56. Ziranu P, Pretta A, Pozzari M, Maccioni A, Badiali M, Fanni D, Lai E, Donisi C, Persano M, Gerosa C, Puzzone M, Bardanzellu F, Ambu R, Pusceddu V, Dubois M, Cerrone G, Migliari M, Murgia S, Spanu D, Pretta G, Aimola V, Balconi F, Murru S, Faa G, Scartozzi M. CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors. *Sci Rep*. 2023 Mar 16;13(1):4397. doi: 10.1038/s41598-023-31538-3. PMID: 36928082; PMCID: PMC10020482.
 57. Bertaglia V, Morelli AM, Solinas C, Aiello MM, Manunta S, Denaro N, Tampellini M, Scartozzi M, Novello S. Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. *Crit Rev Oncol Hematol*. 2023 Apr;184:103954. doi: 10.1016/j.critrevonc.2023.103954. Epub 2023 Mar 5. PMID: 36878396.
 58. Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori

- M, Iijima H, Hiasa Y, Burgio V, Rimassa L, Scartozzi M, Cascinu S, Casadei-Gardini A. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? *Target Oncol.* 2023 Mar;18(2):221-233. doi: 10.1007/s11523-023-00953-x. Epub 2023 Mar 15. PMID: 36920648.
59. Zirano P, Aimola V, Pretta A, Dubois M, Murru R, Liscia N, Cau F, Persano M, Deias G, Palma E, Loi F, Migliari M, Pusceddu V, Puzzone M, Lai E, Cascinu S, Faa G, Scartozzi M. New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression. *Cancers (Basel).* 2023 Feb 14;15(4):1212. doi: 10.3390/cancers15041212. PMID: 36831554; PMCID: PMC9953769.
 60. Madeddu C, Busquets S, Donisi C, Lai E, Pretta A, López-Soriano FJ, Argilés JM, Scartozzi M, Macciò A. Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer. *Cancers (Basel).* 2023 Feb 8;15(4):1076. doi: 10.3390/cancers15041076. PMID: 36831431; PMCID: PMC9953791.
 61. Macciò A, Madeddu C, Lai E, Scartozzi M. Cancer cachexia and chronic inflammation: an unbreakable bond. *Br J Cancer.* 2023 May;128(9):1609-1610. doi: 10.1038/s41416-023-02200-6. Epub 2023 Feb 17. PMID: 36807335; PMCID: PMC9936107.
 62. Fanotto V, Salani F, Vivaldi C, Scartozzi M, Ribero D, Puzzone M, Montagnani F, Leone F, Vasile E, Bencivenga M, De Manzoni G, Basile D, Fornaro L, Masi G, Aprile G. Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. *Cancers (Basel).* 2023 Jan 31;15(3):900. doi: 10.3390/cancers15030900. PMID: 36765854; PMCID: PMC9913845.
 63. Prete AA, Manca P, Messina M, Formica V, Frassinetti GL, Zampino MG, Corsi DC, Orciuolo C, Prisciandaro M, Bergamo F, Angerilli V, Scartozzi M, Casagrande M, Masi G, Ronzoni M, Morano F, Vettore V, Salmaso R, Rasola C, Maddalena G, Del Bianco P, Milione M, Cremolini C, Fassan M, Pietrantonio F, Lonardi S. Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study. *Eur J Cancer.* 2023 Mar;182:87-97. doi: 10.1016/j.ejca.2022.12.025. Epub 2023 Jan 9. PMID: 36753836.
 64. Wekking D, Porcu M, De Silva P, Saba L, Scartozzi M, Solinas C. Breast MRI: Clinical Indications, Recommendations, and Future Applications in Breast Cancer Diagnosis. *Curr Oncol Rep.* 2023 Apr;25(4):257-267. doi: 10.1007/s11912-023-01372-x. Epub 2023 Feb 7. PMID: 36749493.
 65. Fanotto V, Salani F, Vivaldi C, Scartozzi M, Ribero D, Puzzone M, Montagnani F, Leone F, Vasile E, Bencivenga M, De Manzoni G, Basile D, Fornaro L, Masi G, Aprile G. Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. *Cancers (Basel).* 2023 Jan 31;15(3):900. doi: 10.3390/cancers15030900. PMID: 36765854; PMCID: PMC9913845.
 66. Prete AA, Manca P, Messina M, Formica V, Frassinetti GL, Zampino MG, Corsi DC, Orciuolo C, Prisciandaro M, Bergamo F, Angerilli V, Scartozzi M, Casagrande M, Masi G, Ronzoni M, Morano F, Vettore V, Salmaso R, Rasola C, Maddalena G, Del Bianco P, Milione M, Cremolini C, Fassan M, Pietrantonio F, Lonardi S. Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study. *Eur J Cancer.* 2023 Jan 9;182:87-97. doi: 10.1016/j.ejca.2022.12.025. Epub ahead of print. PMID 36753836.
 67. Denaro N, Garrone O, Morelli A, Pellegrino B, Merlano MC, Vacca D, Pearce J, Farci D, Musolino A, Scartozzi M, Tommasi C, Solinas C. A narrative review of the principal glucocorticoids employed in cancer. *Semin Oncol.* 2023 Jan 27:S0093-7754(23)00004-0. doi: 10.1053/j.seminoncol.2023.01.004. Epub ahead of print. PMID: 36737303.
 68. Rimini M, Fabregat-Franco C, Persano M, Burgio V, Bergamo F, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients. *Target Oncol.* 2023 Jan;18(1):139-145. doi: 10.1007/s11523-022-00933-7. Epub 2023 Jan 23. PMID:36689074.
 69. Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa Ramos J, Masi G, Yoo C, Lonardi S, Stefanini B, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Montes M, Vivaldi C, Soldà C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A. Role of the prognostic nutritional index in predicting survival in advanced

- hepatocellular carcinoma treated with atezolizumab plus bevacizumab. *Oncology*. 2023 Jan 19. doi:10.1159/000528818. Epub ahead of print. PMID: 36657420.
70. Saxena S, Jena B, Mohapatra B, Gupta N, Kalra M, Scartozzi M, Saba L, Suri JS. Fused deep learning paradigm for the prediction of O⁶-methylguanine-DNA methyltransferase genotype in glioblastoma patients: A neuro-oncological investigation. *Comput Biol Med*. 2023 Feb;153:106492. doi:10.1016/j.compbio.2022.106492. Epub 2023 Jan 4. PMID: 36621191.
 71. Pretta A, Lai E, Donisi C, Spanu D, Ziranu P, Pusceddu V, Puzzone M, Massa E, Scartozzi M. Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not? *World J Clin Oncol*. 2022 Dec 24;13(12):980-983. doi: 10.5306/wjco.v13.i12.980. PMID: 36618080; PMCID: PMC9813836.
 72. Casadei-Gardini A, Rimini M, Kudo M, Shimose S, Tada T, Suda G, Goh MJ, Jefremow A, Scartozzi M, Cabibbo G, Campani C, Tamburini E, Tovoli F, Ueshima K, Aoki T, Iwamoto H, Torimura T, Kumada T, Hiraoka A, Atsukawa M, Itobayashi E, Toyoda H, Sakamoto N, Sho T, Kang W, Siebler J, Neurath MF, Burgio V, Cascinu S. Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study. *Liver Cancer*. 2022 Jul 11;11(6):527-539. doi: 10.1159/000525145. PMID: 36589723; PMCID: PMC9801178.
 73. Petrelli F, Bertaglia V, Parati MC, Borgonovo K, De Silva P, Luciani A, Novello S, Scartozzi M, Emens LA, Solinas C. Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis. *Breast*. 2023 Feb;67:8-13. doi: 10.1016/j.breast.2022.12.004. Epub 2022 Dec 15. PMID: 36549170; PMCID: PMC9792383
 74. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A. *Eur J Cancer*. 2023 Feb;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25. PMID: 36527976 Clinical Trial.
 75. Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment. Pretta A, Ziranu P, Giampieri R, Donisi C, Cimbri E, Spanu D, Lai E, Pecci F, Balconi F, Lupi A, Pozzari M, Persano M, Murgia S, Pusceddu V, Puzzone M, Berardi R, Scartozzi M. *Dig Liver Dis*. 2022 Dec 10;S1590-8658(22)00787-3. doi: 10.1016/j.dld.2022.11.012. Online ahead of print. PMID: 36513569
 76. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study. Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Kawaguchi T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Cammarota A, Burgio V, Cascinu S, Casadei-Gardini A. *J Cancer Res Clin Oncol*. 2022 Dec 13. doi: 10.1007/s00432-022-04512-1. Online ahead of print. PMID: 36509984
 77. Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm? Tommasi C, Balsano R, Corianò M, Pellegrino B, Saba G, Bardanzellu F, Denaro N, Ramundo M, Toma I, Fusaro A, Martella S, Aiello MM, Scartozzi M, Musolino A, Solinas C. *J Clin Med*. 2022 Dec 6;11(23):7239. doi: 10.3390/jcm11237239. PMID: 36498813 Free PMC article. Review.
 78. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Orsi G, Cavaliere A, Tortora G, Lonardi S, Macchini M, Di Marco M, Giordano G, Vasile E, Scartozzi M, Bozzarelli S, Noventa S, Rodriquenz MG, Militello AM, Rapposelli IG, Garajova I, De Lorenzo S, Merelli B, Bittoni A, Salvatore L, Procaccio L, Paratore C, Spallanzani A, Peretti U, Nigam M, Giommoni E, Bernardini I, Tamburini E, Bernardino

- K, Forti L, Valente MM, Cascinu S, Milella M, Reni M. *Br J Cancer*. 2022 Dec 8. doi: 10.1038/s41416-022-02086-w. Online ahead of print. PMID: 36482190
79. Rare histotypes of epithelial biliary tract tumors: A literature review. Sapuppo E, Brunetti O, Tessitore D, Brandi G, Di Giovanni N, Fadda G, Luchini C, Martini M, Quaresmini D, Russo A, Santarpia M, Scarpa A, Scartozzi M, Tuccari G, Franchina T, Silvestris N. *Crit Rev Oncol Hematol*. 2023 Jan;181:103892. doi: 10.1016/j.critrevonc.2022.103892. Epub 2022 Dec 5. PMID: 36481306 Free article. Review.
 80. Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors? Persano M, Casadei-Gardini A, Burgio V, Scartozzi M, Cascinu S, Rimini M. *Expert Rev Anticancer Ther*. 2023 Jan;23(1):19-27. doi: 10.1080/14737140.2023.2156340. Epub 2022 Dec 14. PMID: 36472371 Review.
 81. Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.
 82. Rimini M, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. *Sci Rep*. 2022 Nov 5;12(1):18775. doi: 10.1038/s41598-022-22543-z. PMID: 36335135 Free PMC article.
 83. The Innate Immune Microenvironment in Metastatic Breast Cancer. Tommasi C, Pellegrino B, Diana A, Palafox Sancez M, Orditura M, Scartozzi M, Musolino A, Solinas C. *J Clin Med*. 2022 Oct 11;11(20):5986. doi: 10.3390/jcm11205986. PMID: 36294305 Free PMC article. Review.
 84. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, Lonardi S, Scartozzi M, Iavarone M, Di Costanzo GG, Marra F, Soldà C, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Pressiani T, Nishida N, Iwamoto H, Sakamoto N, Ryoo BY, Chon HJ, Claudia F, Niizeki T, Sho T, Kang B, D'Alessio A, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimur T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Pedica F, De Cobelli F, Ratti F, Aldrighetti L, Kudo M, Cascinu S, Casadei-Gardini A. *ESMO Open*. 2022 Dec;7(6):100591. doi: 10.1016/j.esmoop.2022.100591. Epub 2022 Oct 6. PMID: 36208496 Free PMC article.
 85. Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters. Rimini M, Loi E, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Zavattari P, Casadei-Gardini A. *Eur J Cancer*. 2022 Nov;175:299-310. doi: 10.1016/j.ejca.2022.08.026. Epub 2022 Sep 28. PMID: 36182816
 86. Does immunotherapy change the treatment paradigm in metastatic gastric cancer? Camera S, Liscia N, Foti S, Barbieri L, Cossu A, Puccetti F, Elmore U, Rosati R, Scartozzi M, Mazza E, Cascinu S. *Med Oncol*. 2022 Sep 29;39(12):224. doi: 10.1007/s12032-022-01819-4. PMID: 36175723 Review.
 87. Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment. Spanu D, Pretta A, Lai E, Persano M, Donisi C, Mariani S, Dubois M, Migliari M, Saba G, Zirano P, Pusceddu V, Puzzone M, Astara G, Scartozzi M. *World J Hepatol*. 2022 Jul 27;14(7):1319-1332. doi: 10.4254/wjh.v14.i7.1319. PMID: 36158925 Free PMC article. Review.
 88. Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib. Sapena V, Iavarone M, Boix L, Facchetti F, Guarino M, Sanduzzi Zamparelli M, Granito A, Samper E, Scartozzi M, Corominas J, Marisi G, Díaz A, Casadei-Gardini A, Gramantieri L, Lampertico P, Morisco F, Torres F, Bruix J, Reig M. *World J Hepatol*. 2022 Jul 27;14(7):1438-1458. doi: 10.4254/wjh.v14.i7.1438. PMID: 36158918 Free PMC article.
 89. Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis. Rimini M, Burgio V, Antonuzzo L, Rimassa L, Oneda E, Lavacchi D, Personeni N, Ratti F, Pedica F, Della Corte A, Persano M, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A. *Target Oncol*. 2022 Sep;17(5):591-596. doi: 10.1007/s11523-022-00917-7. Epub 2022 Sep 17. PMID: 36114954
 90. Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research. Langou Fontsa M, Aiello MM, Migliori E, Scartozzi M, Lambertini M, Willard-Gallo K,

Solinas C. *Target Oncol.* 2022 Sep 14. doi: 10.1007/s11523-022-00908-8. Online ahead of print. PMID: 36102923 Review.

91. Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib. Rimini M, Kang W, Burgio V, Persano M, Aoki T, Shimose S, Tada T, Kumada T, Sho T, Lai E, Celsa C, Campani C, Tonnini M, Tamburini E, Hiraoka A, Takaguchi K, Nishida N, Iwamoto H, Itobayashi E, Tsuji K, Sakamoto N, Ishikawa T, Toyoda H, Kudo M, Kawaguchi T, Hatanaka T, Nouse K, Suda G, Cabibbo G, Marra F, Della Corte A, Ratti F, Pedica F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A. *Hepatol Res.* 2022 Aug 12. doi: 10.1111/hepr.13824. Online ahead of print. PMID: 35960789
92. Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report. Madeddu C, Sanna E, Nemolato S, Mulas O, Oppi S, Scartozzi M, La Nasa G, Maccio A. *Diagnostics (Basel).* 2022 Aug 7;12(8):1910. doi: 10.3390/diagnostics12081910. PMID: 36010260 Free PMC article. Review.
93. Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors. Bertaglia V, Petrelli F, Porcu M, Saba L, Pearce J, Luciani A, Solinas C, Scartozzi M. *Cytokine Growth Factor Rev.* 2022 Oct;67:1-10. doi: 10.1016/j.cytogfr.2022.07.009. Epub 2022 Jul 30. PMID: 35945096
94. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. Rimini M, Macarulla T, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Nappo F, Nichetti F, Lai E, Valgiusti M, Cappetta A, Febregat C, Fassan M, De Braud F, Puzzone M, Frassinetti GL, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. *Eur J Cancer.* 2022 Aug;171:232-241. doi: 10.1016/j.ejca.2022.05.004. Epub 2022 Jun 21. PMID: 35749808
95. Lai E, Puzzone M, Ziranu P, Cremolini C, Lonardi S, Banzi M, Mariani S, Liscia N, Cinieri S, Dettori M, Mencoboni M, Nappo F, Piacentini G, Labianca R, Zucchelli G, Boccaccino A, Conca V, Pusceddu V, Zaniboni A, Scartozzi M; GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente, Italian Group for the Study of Gastrointestinal Tumors). Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study. *Clin Colorectal Cancer.* 2021 Jul 31:S1533-0028(21)00073-6. doi: 10.1016/j.clcc.2021.07.008. Epub ahead of print. PMID: 34429245.
96. Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, Noventa S, Rapposelli IG, Garajova I, Tortora G, Rodriquez MG, Bittoni A, Penzo E, De Lorenzo S, Peretti U, Paratore C, Bernardini I, Mosconi S, Spallanzani A, Macchini M, Tamburini E, Bencardino K, Giommoni E, Scartozzi M, Forti L, Valente MM, Militello AM, Cascinu S, Milella M, Reni M. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. *ESMO Open.* 2021 Aug 12;6(5):100238. doi: 10.1016/j.esmoop.2021.100238. Epub ahead of print. PMID: 34392104; PMCID: PMC8371213.
97. Filippi R, Leone F, Fornaro L, Aprile G, Casadei-Gardini A, Silvestris N, Palloni A, Satolli MA, Scartozzi M, Russano M, Lutrino SE, Lombardi P, Frega G, Garattini SK, Vivaldi C, Spadi R, Giulia O, Fenocchio E, Brunetti O, Aglietta M, Brandi G. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. *J Chemother.* 2021 Jul 27:1-10. doi: 10.1080/1120009X.2021.1953887. Epub ahead of print. PMID: 34313188.
98. Filippi R, Montagnani F, Lombardi P, Fornaro L, Aprile G, Casadei-Gardini A, Faloppi L, Palloni A, Satolli MA, Scartozzi M, Citarella F, Lutrino SE, Vivaldi C, Silvestris N, Rovesti G, Rimini M, Aglietta M, Brandi G, Leone F. A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. *Acta Oncol.* 2021 Jul 20:1-8. doi: 10.1080/0284186X.2021.1953704. Epub ahead of print. PMID: 34282710.
99. Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, Migliari M, Donisi C, Demurtas L, Pusceddu V, Puzzone M, Scartozzi M. BRCA-mutant pancreatic

- ductal adenocarcinoma. *Br J Cancer*. 2021 Jul 14. doi: 10.1038/s41416-021-01469-9. Epub ahead of print. PMID: 34262146.
100. Rapposelli IG, Shimose S, Kumada T, Okamura S, Hiraoka A, Di Costanzo GG, Marra F, Tamburini E, Forgione A, Foschi FG, Silletta M, Lonardi S, Masi G, Scartozzi M, Nakano M, Shibata H, Kawata K, Pellino A, Vivaldi C, Lai E, Takata A, Tajiri K, Toyoda H, Tortora R, Campani C, Viola MG, Piscaglia F, Conti F, Fulgenzi CAM, Frassinetti GL, Rizzato MD, Salani F, Astará G, Torimura T, Atsukawa M, Tada T, Burgio V, Rimini M, Cascinu S, Casadei-Gardini A. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. *ESMO Open*. 2021 Jun 15;6(4):100190. doi: 10.1016/j.esmoop.2021.100190. Epub ahead of print. PMID: 34144271; PMCID: PMC8219999.
 101. Lai E, Cascinu S, Scartozzi M. Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. *Front Oncol*. 2021 May 10;11:637823. doi: 10.3389/fonc.2021.637823. PMID: 34041019; PMCID: PMC8141840.
 102. 8: Rovesti G, Leone F, Brandi G, Cesario S, Scartozzi M, Niger M, Yoo C, Filippi R, Casagrande M, Silvestris N, Santini D, Faloppi L, Palloni A, Aglietta M, Bernardini L, Cho H, Lai E, Fenocchio E, Pircher C, Iacono D, De Lorenzo S, Sperti E, Massa V, De Braud F, Jeong JH, Aprile G, Burgio V, Cascinu S, Casadei-Gardini A. A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. *J Gastrointest Cancer*. 2021 May 25. doi: 10.1007/s12029-021-00649-3. Epub ahead of print. PMID: 34033000.
 103. Ziranu P, Lai E, Schirripa M, Puzzone M, Persano M, Pretta A, Munari G, Liscia N, Pusceddu V, Loupakis F, Demurtas L, Libertini M, Mariani S, Migliari M, Dubois M, Giampieri R, Sotgiu G, Dei Tos AP, Lonardi S, Zaniboni A, Fassan M, Scartozzi M. The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. *Target Oncol*. 2021 Jul;16(4):517-527. doi: 10.1007/s11523-021-00816-3. Epub 2021 May 10. PMID: 33970400; PMCID: PMC8266772.
 104. Sancassiani F, Massa E, Pibia C, Perda G, Boe L, Fantozzi E, Cossu G, Caocci G, Mulas O, Morelli E, Lindert J, Lai E, Nardi AE, Scartozzi M, La Nasa G, Carta MG. The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study. *J Public Health Res*. 2021 May 5. doi: 10.4081/jphr.2021.2247. Epub ahead of print. PMID: 33960184.
 105. Fornaro L, Spallanzani A, de Vita F, D'Ugo D, Falcone A, Lorenzon L, Tirino G, Cascinu S; GAIN (GAstric Cancer Italian Network). Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). *Cancers (Basel)*. 2021 Mar 15;13(6):1304. doi: 10.3390/cancers13061304. PMID: 33804024; PMCID: PMC8001719.
 106. Rosati G, Lonardi S, Galli F, Di Bartolomeo M, Ronzoni M, Zampino MG, Banzi M, Zaniboni A, Pasini F, Bozzarelli S, Garattini SK, Ferrari D, Montesarchio V, Mambrini A, Ciuffreda L, Galli F, Pusceddu V, Carlomagno C, Bidoli P, Amoroso D, Bochicchio AM, Frassinetti L, Corsi D, Bilancia D, Pastorino A, De Stefano A, Labianca R; TOSCA (Three or Six Colon Adjuvant) investigators. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. *Eur J Cancer*. 2021 May;148:190-201. doi: 10.1016/j.ejca.2021.01.051. Epub 2021 Mar 18. PMID: 33744715.
 107. Bang Y, Yoo C, Lonardi S, Kim HD, Vivaldi C, Rimini M, Frassinetti GL, Park SR, Rizzato MD, Ryu MH, Salani F, Rapposelli IG, Ryoo BY, Zagonel V, Massa V, Valgiusti M, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A. Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis. *Target Oncol*. 2021 May;16(3):401-410. doi: 10.1007/s11523-021-00797-3. Epub 2021 Mar 1. Erratum in: *Target Oncol*. 2021 Mar 18;; PMID: 33646487.
 108. Donisi C, Puzzone M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, Pretta A, Liscia N, Astará G, Scartozzi M. Immune Checkpoint Inhibitors in the

- Treatment of HCC. *Front Oncol.* 2021 Jan 7;10:601240. doi: 10.3389/fonc.2020.601240. PMID: 33585218; PMCID: PMC7874239.
109. Casadei-Gardini A, Scartozzi M, Tada T, Yoo C, Shimose S, Masi G, Lonardi S, Frassinetti LG, Nicola S, Piscaglia F, Kumada T, Kim HD, Koga H, Vivaldi C, Soldà C, Hiraoka A, Bang Y, Atsukawa M, Torimura T, Tsuj K, Itobayashi E, Toyoda H, Fukunishi S, Rimassa L, Rimini M, Cascinu S, Cucchetti A. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. *Liver Int.* 2021 Jun;41(6):1389-1397. doi: 10.1111/liv.14817. Epub 2021 Feb 20. PMID: 33547848.
 110. Rovesti G, Leone F, Brandi G, Fornaro L, Scartozzi M, Niger M, Yoo C, Caputo F, Filippi R, Casagrande M, Silvestris N, Santini D, Faloppi L, Palloni A, Aglietta M, Vivaldi C, Cho H, Lai E, Fenocchio E, Nichetti F, Pella N, De Lorenzo S, Di Maio M, Vasile E, de Braud F, Jeong JH, Aprile G, Orsi G, Cascinu S, Casadei-Gardini A. Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. *J Gastrointest Cancer.* 2021 Feb 5. doi: 10.1007/s12029-021-00596-z. Epub ahead of print. PMID: 33544375.
 111. Lai E, Astarà G, Ziranu P, Pretta A, Migliari M, Dubois M, Donisi C, Mariani S, Liscia N, Impera V, Persano M, Tolu S, Balconi F, Pinna G, Spanu D, Pireddu A, Saba G, Camera S, Musio F, Puzzone M, Pusceddu V, Madeddu C, Casadei Gardini A, Scartozzi M. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? *Crit Rev Oncol Hematol.* 2021 Jan;157:103167. doi: 10.1016/j.critrevonc.2020.103167. Epub 2020 Nov 12. PMID: 33271389.
 112. Pretta A, Ziranu P, Puzzone M, Lai E, Orsi G, Liscia N, Molinaro E, Mariani S, Riggi L, Rovesti G, Dubois M, Migliari M, Persano M, Saba G, Impera V, Musio F, Batzella E, Demurtas L, Pusceddu V, Astarà G, Faloppi L, Casadei Gardini A, Andrikou K, Cascinu S, Scartozzi M. Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. *Tumori.* 2020 Nov 26:300891620976945. doi: 10.1177/0300891620976945. Epub ahead of print. PMID: 33243068.
 113. Casadei-Gardini A, Rovesti G, Dadduzio V, Vivaldi C, Lai E, Lonardi S, Fornaro L, Pretta A, Zagonel V, Bernardini L, Astarà G, D'Amico FE, Masi G, Rimini M, Scartozzi M, Cascinu S. Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. *HPB (Oxford).* 2021 Jun;23(6):915-920. doi: 10.1016/j.hpb.2020.09.024. Epub 2020 Nov 12. PMID: 33191108.
 114. Faloppi L, Puzzone M, Gardini AC, Silvestris N, Masi G, Marisi G, Vivaldi C, Gadaleta CD, Ziranu P, Bianconi M, Loretelli C, Demurtas L, Lai E, Giampieri R, Galizia E, Ulivi P, Battelli N, Falcone A, Cascinu S, Scartozzi M. Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. *Target Oncol.* 2020 Dec;15(6):801-802. doi: 10.1007/s11523-020-00773-3. Erratum for: *Target Oncol.* 2020 Feb;15(1):115-126. PMID: 33170485.
 115. Orsi G, Tovoli F, Dadduzio V, Vivaldi C, Brunetti O, Ielasi L, Conti F, Rovesti G, Gramantieri L, Rizzato MD, Pecora I, Argentiero A, Teglia F, Lonardi S, Salani F, Granito A, Zagonel V, Marisi G, Cabibbo G, Foschi FG, Benevento F, Cucchetti A, Piscaglia F, Cascinu S, Scartozzi M, Casadei-Gardini A. Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. *Target Oncol.* 2020 Dec;15(6):809-810. doi: 10.1007/s11523-020-00765-3. Erratum for: *Target Oncol.* 2020 Dec;15(6):773-785. PMID: 33113041.
 116. Orsi G, Tovoli F, Dadduzio V, Vivaldi C, Brunetti O, Ielasi L, Conti F, Rovesti G, Gramantieri L, Rizzato MD, Pecora I, Argentiero A, Teglia F, Lonardi S, Salani F, Granito A, Zagonel V, Marisi G, Cabibbo G, Foschi FG, Benevento F, Cucchetti A, Piscaglia F, Cascinu S, Scartozzi M, Casadei-Gardini A. Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. *Target Oncol.* 2020 Dec;15(6):773-785. doi: 10.1007/s11523-020-00757-3. Erratum in: *Target Oncol.* 2020 Oct 28;; PMID: 33044683.
 117. La Nasa G, Caocci G, Morelli E, Massa E, Farci A, Deiana L, Pintus E, Scartozzi M, Sancassiani F. Health Related Quality of Life in Patients with Onco-hematological Diseases. *Clin*

- Pract Epidemiol Ment Health. 2020 Jul 30;16:174-179. doi: 10.2174/1745017902016010174. PMID: 32874192; PMCID: PMC7431682.
118. Dell'Aquila E, Zeppola T, Stellato M, Pantano F, Scartozzi M, Madaudo C, Pietrantonio F, Cremolini C, Aprile G, Vincenzi B, Moretto R, Puzzoni M, Garattini SK, Lobefaro R, Tonini G, Santini D. Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? *Clin Med Insights Oncol.* 2020 Aug 4;14:1179554920946693. doi: 10.1177/1179554920946693. PMID: 32821190; PMCID: PMC7412900.
 119. Gerosa C, Crisponi G, Nurchi VM, Saba L, Cappai R, Cau F, Faa G, Van Eyken P, Scartozzi M, Floris G, Fanni D. Gold Nanoparticles: A New Golden Era in Oncology? *Pharmaceuticals (Basel).* 2020 Aug 12;13(8):192. doi: 10.3390/ph13080192. PMID: 32806755; PMCID: PMC7464886.
 120. Vega-Benedetti AF, Loi E, Moi L, Orrù S, Ziranu P, Pretta A, Lai E, Puzzoni M, Ciccone L, Casadei-Gardini A, Cabras F, Fortunato F, Restivo A, Zorcolo L, Scartozzi M, Zavattari P. Colorectal Cancer Early Detection in Stool Samples Tracing CpG Islands Methylation Alterations Affecting Gene Expression. *Int J Mol Sci.* 2020 Jun 24;21(12):4494. doi: 10.3390/ijms21124494. PMID: 32599859; PMCID: PMC7349989.
 121. Neuzillet C, Casadei-Gardini A, Brieu B, Vivaldi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Le Sourd S, Evesque L, Meurisse A, Lièvre A, Vernerey D; AGEO (Association des Gastro-Entérologues Oncologues) Investigators; GICO (Italian Group of Cholangiocarcinoma) Investigators. Flutopyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. *Int J Cancer.* 2020 Dec 1;147(11):3177-3188. doi: 10.1002/ijc.33146. Epub 2020 Jul 7. PMID: 32525595.
 122. Casadei-Gardini A, Dadduzio V, Rovesti G, Cabibbo G, Vukotic R, Rizzato MD, Orsi G, Rossi M, Guarneri V, Lonardi S, D'agostino D, Celsa C, Andreone P, Zagonel V, Scartozzi M, Cascinu S, Cucchetti A. Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. *Medicine (Baltimore).* 2020 May 29;99(22):e19958. doi: 10.1097/MD.00000000000019958. PMID: 32481366.
 123. Rossini D, Germani MM, Pagani F, Pellino A, Dell'Aquila E, Bensi M, Liscia N, Moretto R, Boccaccino A, Prisciandaro M, Manglaviti S, Schirripa M, Vivolo R, Scartozzi M, Santini D, Salvatore L, Pietrantonio F, Loupakis F, Falcone A, Cremolini C. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. *Clin Colorectal Cancer.* 2020 Sep;19(3):191-199.e6. doi: 10.1016/j.clcc.2020.03.009. Epub 2020 Apr 11. PMID: 32466976.
 124. Giampieri R, Ziranu P, Daniele B, Zizzi A, Ferrari D, Lonardi S, Zaniboni A, Cavanna L, Rosati G, Casagrande M, Pella N, Demurtas L, Zampino MG, Sozzi P, Pusceddu V, Germano D, Lai E, Zagonel V, Codecà C, Libertini M, Puzzoni M, Labianca R, Cascinu S, Scartozzi M. From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. *Cancers (Basel).* 2020 May 22;12(5):1330. doi: 10.3390/cancers12051330. PMID: 32456056; PMCID: PMC7281010.
 125. Pasqualetti G, Schirripa M, Dochy E, Fassan M, Ziranu P, Puzzoni M, Scartozzi M, Alberti G, Lonardi S, Zagonel V, Monzani F, Loupakis F. Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. *Eur J Cancer.* 2020 Jul;133:66-73. doi: 10.1016/j.ejca.2020.04.023. Epub 2020 May 20. PMID: 32446145.
 126. Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessi M, Astara G, Madeddu C, Scartozzi M. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. *Cancers (Basel).* 2020 May 13;12(5):1214. doi: 10.3390/cancers12051214. PMID: 32413973; PMCID: PMC7281737.

127. Caputo F, Dadduzio V, Tovoli F, Bertolini G, Cabibbo G, Cerma K, Vivaldi C, Faloppi L, Rizzato MD, Piscaglia F, Celsa C, Fornaro L, Marisi G, Conti F, Silvestris N, Silletta M, Lonardi S, Granito A, Stornello C, Massa V, Astara G, Delcuratolo S, Cascinu S, Scartozzi M, Casadei-Gardini A. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. *PLoS One*. 2020 May 7;15(5):e0232449. doi: 10.1371/journal.pone.0232449. PMID: 32379785; PMCID: PMC7205300.
128. Casadei-Gardini A, Marisi G, Dadduzio V, Gramantieri L, Faloppi L, Ulivi P, Foschi FG, Tamburini E, Vivaldi C, Rizzato MD, Ielasi L, Canale M, Conti F, Rudnas B, Fornaro L, Silvestris N, Silletta M, Cardellino GG, Lonardi S, Fornari F, Orsi G, Rovesti G, Zagonel V, Cascinu S, Scartozzi M. Association of *NOS3* and *ANGPT2* Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. *Clin Cancer Res*. 2020 Sep 1;26(17):4485-4493. doi: 10.1158/1078-0432.CCR-19-3897. Epub 2020 May 5. PMID: 32371540.
129. Casadei-Gardini A, Vagheggini A, Gelsomino F, Spallanzani A, Ulivi P, Orsi G, Rovesti G, Andrikou K, Tamburini E, Scartozzi M, Cascinu S. Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. *Clin Colorectal Cancer*. 2020 Jun;19(2):82-90.e9. doi: 10.1016/j.clcc.2019.10.001. Epub 2020 Mar 17. PMID: 32192883.
130. Faloppi L, Puzzone M, Casadei Gardini A, Silvestris N, Masi G, Marisi G, Vivaldi C, Gadaleta CD, Ziranu P, Bianconi M, Loretelli C, Demurtas L, Lai E, Giampieri R, Galizia E, Ulivi P, Battelli N, Falcone A, Cascinu S, Scartozzi M. Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. *Target Oncol*. 2020 Feb;15(1):115-126. doi: 10.1007/s11523-020-00698-x. Erratum in: *Target Oncol*. 2020 Dec;15(6):801-802. PMID: 32020517.
131. Puzzone M, Ziranu P, Demurtas L, Lai E, Mariani S, Liscia N, Soro P, Pretta A, Impera V, Camera S, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Scartozzi M. Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients. *Future Oncol*. 2020 Jan;16(2):4337-4339. doi: 10.2217/fon-2019-0624. Epub 2019 Dec 3. Erratum in: *Future Oncol*. 2020 Feb;16(6):219. PMID: 31793396.
132. Salati M, Filippi R, Vivaldi C, Caputo F, Leone F, Salani F, Cerma K, Aglietta M, Fornaro L, Sperti E, Di Maio M, Ortega C, Fenocchio E, Lombardi P, Cagnazzo C, Depetris I, Gelsomino F, Spallanzani A, Santini D, Silvestris N, Aprile G, Roviello G, Scartozzi M, Cascinu S, Casadei-Gardini A. The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. *Liver Int*. 2020 Mar;40(3):704-711. doi: 10.1111/liv.14314. Epub 2019 Dec 11. PMID: 31773848.
133. Rovesti G, Orsi G, Kalliopi A, Vivaldi C, Marisi G, Faloppi L, Foschi FG, Silvestris N, Pecora I, Aprile G, Molinaro E, Riggi L, Ulivi P, Canale M, Cucchetti A, Tamburini E, Ercolani G, Fornaro L, Andreone P, Zavattari P, Scartozzi M, Cascinu S, Casadei-Gardini A. Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. *Gastrointest Tumors*. 2019 Oct;6(3-4):92-107. doi: 10.1159/000502714. Epub 2019 Sep 12. PMID: 31768353; PMCID: PMC6873043.
134. Casadei-Gardini A, Solaini L, Riggi L, Molinaro E, Dadduzio V, Rizzato MD, Pellino A, Faloppi L, Marisi G, Ulivi P, Canale M, Orsi G, Rovesti G, Andrikou K, Spallanzani A, Gelsomino F, Foschi FG, Conti F, Cucchetti A, Ercolani G, Biason P, Lonardi S, Cascinu S, Scartozzi M. Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. *Gastrointest Tumors*. 2019 Oct;6(3-4):71-80. doi: 10.1159/000501593. Epub 2019 Aug 20. PMID: 31768351; PMCID: PMC6873000.
135. Lai E, Puzzone M, Ziranu P, Pretta A, Impera V, Mariani S, Liscia N, Soro P, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Pireddu A, Demurtas L, Pusceddu V, Camera S, Sclafani F, Scartozzi M. New therapeutic targets in pancreatic cancer. *Cancer Treat Rev*. 2019 Dec;81:101926. doi: 10.1016/j.ctrv.2019.101926. Epub 2019 Nov 11. PMID: 31739115.
136. Colombino M, Paliogiannis P, Cossu A, Santeufemia DA; Sardinian Lung Cancer (SLC) Study Group, Sini MC, Casula M, Palomba G, Manca A, Pisano M, Doneddu V, Palmieri G. EGFR,

- KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. *BMC Pulm Med.* 2019 Nov 11;19(1):209. doi: 10.1186/s12890-019-0964-x. PMID: 31711449; PMCID: PMC6849322.
137. Neri M, Peiretti M, Melis GB, Piras B, Vallerino V, Paoletti AM, Madeddu C, Scartozzi M, Mais V. Systemic therapy for the treatment of endometrial cancer. *Expert Opin Pharmacother.* 2019 Nov;20(16):2019-2032. doi: 10.1080/14656566.2019.1654996. Epub 2019 Aug 26. PMID: 31451034.
138. Marisi G, Petracci E, Raimondi F, Faloppi L, Foschi FG, Lauletta G, Iavarone M, Canale M, Valgiusti M, Neri LM, Ulivi P, Orsi G, Rovesti G, Vukotic R, Conti F, Cucchetti A, Ercolani G, Andrikou K, Cascinu S, Scartozzi M, Casadei-Gardini A. *ANGPT2* and *NOS3* Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. *Cancers (Basel).* 2019 Jul 20;11(7):1023. doi: 10.3390/cancers11071023. PMID: 31330833; PMCID: PMC6679015.
139. Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I, Bion P, Lonardi S, Zagonel V, Fassan M, Di Maio M. A validated prognostic classifier for ^{V600E}BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. *Eur J Cancer.* 2019 Sep;118:121-130. doi: 10.1016/j.ejca.2019.06.008. Epub 2019 Jul 19. PMID: 31330487.
140. Vega-Benedetti AF, Loi E, Moi L, Blois S, Fadda A, Antonelli M, Arcella A, Badiali M, Giangaspero F, Morra I, Columbano A, Restivo A, Zorcolo L, Gismondi V, Varesco L, Bellomo SE, Giordano S, Canale M, Casadei-Gardini A, Faloppi L, Puzzone M, Scartozzi M, Ziranu P, Cabras G, Cocco P, Ennas MG, Satta G, Zucca M, Canzio D, Zavattari P. Clustered protocadherins methylation alterations in cancer. *Clin Epigenetics.* 2019 Jul 9;11(1):100. doi: 10.1186/s13148-019-0695-0. PMID: 31288858; PMCID: PMC6617643.
141. Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloï D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, Franco P. Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier). *Cancer Manag Res.* 2019 Apr 26;11:3631-3642. doi: 10.2147/CMAR.S197349. Erratum in: *Cancer Manag Res.* 2019 Jun 25;11:5123. PMID: 31118786; PMCID: PMC6506779.
142. Casadei Gardini A, Puzzone M, Montagnani F, Marisi G, Tamburini E, Cucchetti A, Solaini L, Foschi FG, Conti F, Ercolani G, Cascinu S, Scartozzi M. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials. *Onco Targets Ther.* 2019 Apr 24;12:2981-2988. doi: 10.2147/OTT.S192572. PMID: 31118665; PMCID: PMC6499482.
143. Madeddu C, Kotsonis P, Lavra F, Chiappe G, Melis L, Mura E, Scartozzi M, Macciò A. Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer. *Oncotarget.* 2019 Mar 12;10(21):2012-2021. doi: 10.18632/oncotarget.26769. PMID: 31007844; PMCID: PMC6459345.
144. Brunetti O, Luchini C, Argentiero A, Tommasi S, Mangia A, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Santini D, Doglioni C, Maiello E, Lawlor RT, Mazzaferro V, Lonardi S, Giuliente F, Brandi G, Scarpa A, Cascinu S, Silvestris N. The Italian Rare Pancreatic Exocrine Cancer Initiative. *Tumori.* 2019 Aug;105(4):353-358. doi: 10.1177/0300891619839461. Epub 2019 Apr 9. Erratum in: *Tumori.* 2020 Dec;106(6):526. PMID: 30967031.

145. Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassinetti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. *BMC Cancer*. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3. PMID: 30922323; PMCID: PMC6440108.
146. De Matteis S, Scarpi E, Granato AM, Vespasiani-Gentilucci U, La Barba G, Foschi FG, Bandini E, Ghetti M, Marisi G, Cravero P, Gramantieri L, Cucchetti A, Ercolani G, Santini D, Frassinetti GL, Faloppi L, Scartozzi M, Cascinu S, Casadei-Gardini A. Role of SIRT-3, p-mTOR and HIF-1 α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. *Int J Mol Sci*. 2019 Mar 26;20(6):1503. doi: 10.3390/ijms20061503. PMID: 30917505; PMCID: PMC6470641.
147. Porcu M, De Silva P, Solinas C, Battaglia A, Schena M, Scartozzi M, Bron D, Suri JS, Willard-Gallo K, Sangiolo D, Saba L. Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. *Cancers (Basel)*. 2019 Mar 5;11(3):305. doi: 10.3390/cancers11030305. PMID: 30841554; PMCID: PMC6468855.
148. Neuzillet C, Casadei Gardini A, Brieu B, Vivaldi C, Smolenschi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Boussaha T, Malka D, Crusz SM, Le Sourd S, Meurisse A, Lièvre A, Vernerey D; AGEO (Association des Gastro-Entérologues Oncologues); GICO (Italian Group of Cholangiocarcinoma) Investigators; Gustave Roussy Institute Cohort; Barts Cancer Institute Cohort. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. *Eur J Cancer*. 2019 Apr;111:94-106. doi: 10.1016/j.ejca.2019.01.019. Epub 2019 Mar 1. PMID: 30826661.
149. Cascinu S, Poli D, Zaniboni A, Lonardi S, Labianca R, Sobrero A, Rosati G, Di Bartolomeo M, Scartozzi M, Zagonel V, Pella N, Banzi M, Torri V. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. *Eur J Cancer*. 2019 Apr;111:1-7. doi: 10.1016/j.ejca.2019.01.020. Epub 2019 Feb 21. PMID: 30797014
150. Bianconi M, Cimadamore A, Faloppi L, **Scartozzi M**, Santoni M, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R. Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. *Ther Adv Urol*. 2019 Jan 8;11:1756287218815372. doi: 10.1177/1756287218815372. eCollection 2019 Jan-Dec. Review. PubMed PMID: 30671136; PubMed Central PMCID: PMC6329040.
151. Fanotto V, Fornaro L, Bordonaro R, Rosati G, Rimassa L, Di Donato S, Santini D, Tomasello G, Leone F, Silvestris N, Stragliotto S, **Scartozzi M**, Giampieri R, Nichetti F, Antonuzzo L, Cinieri S, Avallone A, Pellegrino A, Melisi D, Vasile E, Gerratana L, Aprile G. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. *J Geriatr Oncol*. 2018 Dec 11. pii: S1879-4068(18)30300-X. doi: 10.1016/j.jgo.2018.11.009. [Epub ahead of print] PubMed PMID: 30551958.
152. Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, **Scartozzi M**, Willard-Gallo K, Mariotti S, Saba L. Cancer immunotherapy-associated hypophysitis. *Semin Oncol*. 2018 Jun;45(3):181-186. doi: 10.1053/j.seminoncol.2018.09.002. Epub 2018 Oct 21. Review. PubMed PMID: 30352754.
153. Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassinetti GL, **Scartozzi M**, Casadei Gardini A. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? *World J*

- Gastroenterol. 2018 Sep 28;24(36):4152-4163. doi: 10.3748/wjg.v24.i36.4152. Review. PubMed PMID: 30271080; PubMed Central PMCID: PMC6158485.
154. Schirripa M, Pasqualetti G, Giampieri R, **Scartozzi M**, Lonardi S, Rumanò L, Bergamo F, Stragliotto S, Murgioni S, Alberti G, Rizzato MD, Prete AA, Puzzone M, Pusceddu V, Ziranu P, Pani F, Mariotti S, Zagonel V, Monzani F, Loupakis F. Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study. *Clin Colorectal Cancer*. 2018 Sep;17(3):e601-e615. doi: 10.1016/j.clcc.2018.05.013. Epub 2018 Jun 8. PubMed PMID: 30149875.
155. Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G, **Scartozzi M**, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G, Frassinetti GL, Casadei Gardini A. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. *Crit Rev Oncol Hematol*. 2018 Sep;129:44-53. doi: 10.1016/j.critrevonc.2018.06.017. Epub 2018 Jun 23. Review. PubMed PMID: 0097237.
156. 0097237.
157. Santini D, Brandi G, Aprile G, Russano M, Cereda S, Leone F, Lonardi S, Fornaro L, **Scartozzi M**, Silvestris N, Barni S, Pantano F, Vincenzi B, Palloni A, Frega G, Casagrande M, Ferrari L, Dadduzio V, Intini R, Filippi R, Vasile E, Vivaldi C, Faloppi L, Brunetti O, Reni M, Aglietta M, Tonini G. Bone metastases in biliary cancers: A multicenter retrospective survey. *J Bone Oncol*. 2018 Apr 7;12:33-37. doi: 10.1016/j.jbo.2017.11.006. eCollection 2018 Sep. PubMed PMID: 30042924; PubMed Central PMCID: PMC6054714.
158. Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, **Scartozzi M**, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. *Anticancer Drugs*. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632. PubMed PMID: 298462
159. Brunetti O, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, **Scartozzi M**, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Scarpa A, Basile D, Mazzuca F, Graziano G, Argentiero A, Santini D, Reni M, Cascinu S, Silvestris N. Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. *Pancreas*. 2018 Jul;47(6):759-771. doi: 10.1097/MPA.0000000000001063. PubMed PMID: 29771769.
160. Porcu M, Solinas C, Garofalo P, de Azambuja E, **Scartozzi M**, Willard-Gallo K, Preusser M, Saba L. Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going? *Crit Rev Oncol Hematol*. 2018 Jun;126:135-144. doi: 10.1016/j.critrevonc.2018.03.026. Epub 2018 Apr 7. Review. PubMed PMID: 29759556.
161. Casadei Gardini A, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J, Chessa L, Bruno D, Ercolani G, Leonetti A, de Stefano G, Farella N, Foschi FG, Lanzi A, Dadduzio V, Marisi G, Masi G, Negri FV, Pagan F, Santini D, Scarpi E, Silletta M, Silvestris N, Tamburini E, Tassinari D, Vivaldi C, Gentilucci UV, Zagonel V, Calveti L, Cascinu S, Frassinetti GL, **Scartozzi M**. Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol. *Tumori*. 2017 Dec 1:tj5000704. doi: 10.5301/tj.5000704. [Epub ahead of print] PubMed PMID: 29739298.
162. Franco P, Montagnani F, Arcadipane F, Casadei C, Andrikou K, Martini S, Iorio GC, **Scartozzi M**, Mistrangelo M, Fornaro L, Cassoni P, Cascinu S, Ricardi U, Casadei Gardini A. The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. *Radiat Oncol*. 2018 May 2;13(1):83. doi: 10.1186/s13014-018-1035-9. PubMed PMID: 29720197; PubMed Central PMCID: PMC5930791.
163. Lai E, Pretta A, Impera V, Mariani S, Giampieri R, Casula L, Pusceddu V, Coni P, Fanni D, Puzzone M, Demurtas L, Ziranu P, Faa G, Scartozzi M. BRAF-mutant colorectal cancer, a different breed evolving. *Expert Rev Mol Diagn*. 2018 Jun;18(6):499-512. doi: 10.1080/14737159.2018.1470928. Epub 2018 May 9. PubMed PMID: 29708446.

165. Madeddu C, Gramignano G, Kotsonis P, Coghe F, Atzeni V, **Scartozzi M**, Macciò A. Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of Interleukin-6. *Haematologica*. 2018 Apr 19. pii: haematol.2018.191551. doi: 10.3324/haematol.2018.191551. [Epub ahead of print] PubMed PMID: 29674498.
166. Sobrero A, Lonardi S, Rosati G, Di Bartolomeo M, Ronzoni M, Pella N, **Scartozzi M**, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Zagonel V, Maiello E, Barni S, Rulli E, Labianca R; TOSCA Investigators. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. *J Clin Oncol*. 2018 May 20;36(15):1478-1485. doi: 10.1200/JCO.2017.76.2187. Epub 2018 Apr 5. PubMed PMID: 29620994.
167. Fornaro L, Scartozzi M, Aprile G. CALGB 80101 and the Final Call for Preoperative Chemotherapy in Gastric Cancer. *J Clin Oncol*. 2018 Apr 10;36(11):1178-1179. doi: 10.1200/JCO.2017.76.6493. Epub 2018 Feb 28. PubMed PMID: 29489431.
168. Battaglin F, Schirripa M, Buggin F, Pietrantonio F, Morano F, Boscolo G, Tonini G, Lutrino ES, Lucchetti J, Salvatore L, Passardi A, Cremolini C, Arnoldi E, **Scartozzi M**, Pella N, Boni L, Bergamo F, Zagonel V, Loupakis F, Lonardi S. The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. *BMC Cancer*. 2018 Jan 25;18(1):98. doi: 10.1186/s12885-018-4001-x. PubMed PMID: 29370781.
169. Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzone M, Willard-Gallo K, **Scartozzi M**, Saba L. Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. *Crit Rev Oncol Hematol*. 2017 Dec;120:13-21. doi: 10.1016/j.critrevonc.2017.09.017. Epub 2017 Oct 10. Review. PubMed PMID: 29198327.
170. Casadei Gardini A, Santini D, Aprile G, Silvestris N, Felli E, Foschi FG, Ercolani G, Marisi G, Valgiusti M, Passardi A, Puzzone M, Silletta M, Brunetti O, Cardellino GG, Frassinetti GL, **Scartozzi M**. Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. *Oncotarget*. 2017 Jul 22;8(39):66699-66708. doi: 10.18632/oncotarget.19449. eCollection 2017 Sep 12. Review. PubMed PMID: 29029548; PubMed Central PMCID: PMC5630448.
171. Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G, Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi A, Santini D, Cascinu S, Frassinetti GL, **Scartozzi M**. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. *Eur J Cancer*. 2017 Nov;86:106-114. doi: 10.1016/j.ejca.2017.09.003. Epub 2017 Oct 3. PubMed PMID: 28985579.
172. Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Donato SD, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, **Scartozzi M**, Avallone A, Lutrino SE, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G. Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. *Future Oncol*. 2017 Oct;13(25):2265-2275. doi: 10.2217/fon-2017-0246. Epub 2017 Oct 4. PubMed PMID: 28976226.
173. Giampieri R, Puzzone M, Daniele B, Ferrari D, Lonardi S, Zaniboni A, Cavanna L, Rosati G, Pella N, Zampino MG, Sozzi P, Germano D, Zagonel V, Codecà C, Libertini M, Labianca R, Cascinu S, **Scartozzi M**; Italian Group for the Study of Gastrointestinal Cancer (GISCAD), Scartozzi M. First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAILdh) trial. *Br J Cancer*. 2017 Oct 10;117(8):1099-1104. doi: 10.1038/bjc.2017.234. Epub 2017 Sep 19. PubMed PMID: 28926529; PubMed Central PMCID: PMC5674092.

174. Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, **Scartozzi M**, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia, Russano M, Aprile G. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. *Oncologist*. 2017 Dec;22(12):1463-1469. doi: 10.1634/theoncologist.2017-0158. Epub 2017 Aug 31. PubMed PMID: 28860412; PubMed Central PMCID: PMC5728025.
175. Pani F, Macerola E, Basolo F, Boi F, **Scartozzi M**, Mariotti S. Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report. *Oncol Lett*. 2017 Aug;14(2):2186-2190. doi: 10.3892/ol.2017.6395. Epub 2017 Jun 16. PubMed PMID: 28781658; PubMed Central PMCID: PMC5530175.
176. Di Costanzo GG, Casadei Gardini A, Marisi G, Foschi FG, **Scartozzi M**, Granata R, Faloppi L, Cascinu S, Silvestris N, Brunetti O, Palmieri VO, Ercolani G, Tortora R. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. *Target Oncol*. 2017 Dec;12(6):795-803. doi: 10.1007/s11523-017-0522-5. PubMed PMID: 28770532.
177. Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferrau F, Labianca R, Ronzoni M, **Scartozzi M**, Galli F; GISCAD investigators. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. *Eur J Cancer*. 2017 Sep;83:106-115. doi: 10.1016/j.ejca.2017.06.029. Epub 2017 Jul 20. PubMed PMID: 28735067.
178. Meriggi F, Codignola C, Beretta GD, Ceresoli GL, Caprioli A, **Scartozzi M**, Fraccon AP, Prochilo T, Ogliosi C, Zaniboni A. Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy. *Tumori*. 2017 Sep 18;103(5):443-448. doi: 10.5301/tj.5000632. Epub 2017 Jul 14. PubMed PMID: 28731495.
179. Demurtas L, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Mandolesi A, Cremolini C, Masi G, Gelsomino F, Antoniotti C, Loretelli C, Meriggi F, Zaniboni A, Falcone A, Cascinu S, **Scartozzi M**. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. *Br J Cancer*. 2017 Jul 25;117(3):315-321. doi: 10.1038/bjc.2017.178. Epub 2017 Jun 20. PubMed PMID:28632725; PubMed Central PMCID: PMC5537494.
180. Aprile G, Negri FV, Giuliani F, De Carlo E, Melisi D, Simionato F, Silvestris N, Brunetti O, Leone F, Marino D, Santini D, Dell'Aquila E, Zeppola T, Puzzoni M, **Scartozzi M**. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? *Crit Rev Oncol Hematol*. 2017 Jul;115:1-12. doi: 10.1016/j.critrevonc.2017.03.025. Epub 2017 Apr 20. Review. PubMed PMID: 28602164.
181. Garattini SK, Basile D, Cattaneo M, Fanotto V, Ongaro E, Bonotto M, Negri FV, Berenato R, Ermacora P, Cardellino GG, Giovannoni M, Pella N, **Scartozzi M**, Antonuzzo L, Silvestris N, Fasola G, Aprile G. Molecular classifications of gastric cancers: Novel insights and possible future applications. *World J Gastrointest Oncol*. 2017 May 15;9(5):194-208. doi: 10.4251/wjgo.v9.i5.194. Review. PubMed PMID: 28567184; PubMed Central PMCID: PMC5434387.
182. De Matteis S, Granato AM, Napolitano R, Molinari C, Valgiusti M, Santini D, Foschi FG, Ercolani G, Vespasiani Gentilucci U, Faloppi L, **Scartozzi M**, Frassinetti GL, Casadei Gardini A. Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma. *Dig Dis Sci*. 2017 May 19. doi:10.1007/s10620-017-4615-x. [Epub ahead of print] Review. PubMed PMID: 28527050.
183. Solinas C, Ceppi M, Lambertini M, **Scartozzi M**, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus

- trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. *Cancer Treat Rev.* 2017 Jun;57:8-15. doi: 10.1016/j.ctrv.2017.04.005. Epub 2017 May 2. Review. PubMed PMID: 28525810.
184. Pani F, Massidda M, Pusceddu V, Puzzoni M, Massa E, Madeddu C, **Scartozzi M**, Mariotti S. Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? *Eur J Endocrinol.* 2017 Jul;177(1):85-92. doi: 10.1530/EJE-17-0231. Epub 2017 May 3. PubMed PMID: 28468766.
185. Longo V, Gnoni A, Casadei Gardini A, Pisconti S, Licchetta A, **Scartozzi M**, Memeo R, Palmieri VO, Aprile G, Santini D, Nardulli P, Silvestris N, Brunetti O. Immunotherapeutic approaches for hepatocellular carcinoma. *Oncotarget.* 2017 May 16;8(20):33897-33910. doi: 10.18632/oncotarget.15406. Review. PubMed PMID: 28420805.
186. Giampieri R, Prete MD, Prochilo T, Puzzoni M, Pusceddu V, Pani F, Maccaroni E, Mascia R, Baleani MG, Meletani T, Berardi R, Lanzillo AM, Mariotti S, Zaniboni A, Cascinu S, **Scartozzi M**. Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. *Sci Rep.* 2017 Apr 5;7:45703. doi: 10.1038/srep45703. PubMed PMID: 28378839; PubMed Central PMCID: PMC5380985.
187. Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, Fanotto V, De Carlo E, Loupakis F, Urbano F, Negri FV, Pella N, Russano M, Brunetti O, **Scartozzi M**, Santini D, Silvestris N, Casadei Gardini A, Puzzoni M, Calvetti L, Cardarelli N, Aprile G. Immunotherapy for colorectal cancer: where are we heading? *Expert Opin Biol Ther.* 2017 Jun;17(6):709-721. doi: 10.1080/14712598.2017.1315405. Epub 2017 Apr 13. PubMed PMID: 28375039.
188. Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V, Cattaneo M, Partelli S, **Scartozzi M**, Aprile G, Casadei Gardini A, Morganti AG, Valentini V, Scarpa A, Falconi M, Calabrese A, Lorusso V, Reni M, Cascinu S. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. *Crit Rev Oncol Hematol.* 2017 Mar;111:152-165. doi: 10.1016/j.critrevonc.2017.01.015. Epub 2017 Feb 4. Review. PubMed PMID: 28259290.
189. Casadei Gardini A, Foca F, **Scartozzi M**, Silvestris N, Tamburini E, Faloppi L, Brunetti O, Rudnas B, Pisconti S, Valgiusti M, Marisi G, Foschi FG, Ercolani G, Tassinari D, Cascinu S, Frassinetti GL. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. *Sci Rep.* 2017 Feb 13;7:42499. doi: 10.1038/srep42499. PubMed PMID: 28211921; PubMed Central PMCID: PMC5304169.
190. Solinas C, Chanzá NM, Awada A, **Scartozzi M**. The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. *Cancer Treat Rev.* 2016 Dec 30;53:138-145. doi: 10.1016/j.ctrv.2016.12.004. [Epub ahead of print] Review. PubMed PMID: 28113097.
191. Solinas C, Pusole G, Demurtas L, Puzzoni M, Mascia R, Morgan G, Giampieri R, **Scartozzi M**. Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. *Crit Rev Oncol Hematol.* 2017 Feb;110:106-116. doi: 10.1016/j.critrevonc.2016.11.016. Review. PubMed PMID: 28109400.
192. Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, **Scartozzi M**, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Torri V, Aprile G. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. *Gastric Cancer.* 2016 Dec 27. doi: 10.1007/s10120-016-0681-6. [Epub ahead of print] PubMed PMID: 28028664.
193. Capelli L, Casadei Gardini A, Scarpi E, Frassinetti GL, Saragoni L, Puccetti M, **Scartozzi M**, Giannini M, Tamberi S, Corbelli J, Ulivi P. No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). *Sci Rep.* 2016 Nov 25;6:37621. doi: 10.1038/srep37621. PubMed PMID: 27886225; PubMed Central PMCID: PMC5122846.
194. Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, **Scartozzi M**, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L,

- Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R; TOSCA (Three or Six Colon Adjuvant) Investigators.. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. *Ann Oncol*. 2016 Nov;27(11):2074-2081.
195. PubMed PMID: 27573560.
196. Bianconi M, Faloppi L, Loretelli C, Zizzi A, Giampieri R, Bittoni A, Andrikou K, Del Prete M, Burattini L, Montironi R, **Scartozzi M (corr Author)**, Cascinu S. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. *Oncotarget*. 2016 Jun 21;7(25):37599-37607. doi: 10.18632/oncotarget.9229. PubMed PMID: 27175586; PubMed Central PMCID: PMC5122335.
197. Madeddu C, Deidda M, Piras A, Cadeddu C, Demurtas L, Puzzoni M, Piscopo G, **Scartozzi M**, Mercurio G. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. *J Cardiovasc Med (Hagerstown)*. 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e12-e18. PubMed PMID: 27755238.
198. Palomba G, Doneddu V, Cossu A, Paliogiannis P, Manca A, Casula M, Colombino M, Lanzillo A, Defraia E, Pazzola A, Sanna G, Putzu C, Ortu S, **Scartozzi M**, Ionta MT, Baldino G, Sarobba G, Capelli F, Sedda T, Viridis L, Barca M, Gramignano G, Budroni M, Tanda F, Palmieri G. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. *J Transl Med*. 2016 Oct 13;14(1):292. PubMed PMID: 27737711; PubMed Central PMCID: PMC5064898.
199. Cadeddu C, Piras A, Dessì M, Madeddu C, Mantovani G, **Scartozzi M**, Hagendorff A, Colonna P, Mercurio G. Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy. *Int J Cardiovasc Imaging*. 2016 Oct 1. [Epub ahead of print] PubMed PMID: 27696298.
200. Casadei Gardini A, Scarpi E, Faloppi L, **Scartozzi M**, Silvestris N, Santini D, de Stefano G, Marisi G, Negri FV, Foschi FG, Valgiusti M, Ercolani G, Frassiniet GL. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. *Oncotarget*. 2016 Oct 11;7(41):67142-67149. doi: 10.18632/oncotarget.11565. PubMed PMID: 27613839.
201. Pietrantonio F, Caporale M, Morano F, **Scartozzi M**, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. *Int J Cancer*. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408. PubMed PMID: 27578417.
202. Giampieri R, Restivo A, Pusceddu V, Del Prete M, Maccaroni E, Bittoni A, Faloppi L, Andrikou K, Bianconi M, Cabras F, Berardi R, Zorcolo L, Scintu F, Cascinu S, **Scartozzi M**. The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. *Clin Colorectal Cancer*. 2016 Aug 4. pii: S1533-0028(16)30118-9. doi: 10.1016/j.clcc.2016.07.011. [Epub ahead of print] PubMed PMID: 27576095.
203. Fanotto V, Ongaro E, Rihawi K, Avallone A, Silvestris N, Fornaro L, Vasile E, Antonuzzo L, Leone F, Rosati G, Giuliani F, Bordonaro R, **Scartozzi M**, De Maglio G, Negri FV, Fasola G, Aprile G. HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. *Oncotarget*. 2016 Oct 18;7(42):69060-69074. doi: 10.18632/oncotarget.11264. Review. PubMed PMID: 27542243.
204. Zorcolo L, **Scartozzi M**, Restivo A. Aspirin and Cancer Risk. *JAMA Oncol*. 2016 Oct 1;2(10):1371. doi: 10.1001/jamaoncol.2016.2311. PubMed PMID: 27533621.
205. Palomba G, Cossu A, Paliogiannis P, Pazzola A, Baldino G, **Scartozzi M**, Ionta MT, Ortu S, Capelli F, Lanzillo A, Sedda T, Sanna G, Barca M, Viridis L, Budroni M, Palmieri G. Prognostic

- role of KRAS mutations in Sardinian patients with colorectal carcinoma. *Oncol Lett.* 2016 Aug;12(2):1415-1421. PubMed PMID: 27446446; PubMed Central PMCID: PMC4950545.
206. Scartozzi M, Vincent L, Chiron M, Cascinu S. Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC). *Target Oncol.* 2016 Aug;11(4):489-500. doi: 10.1007/s11523-016-0447-4. PubMed PMID: 27412031.
 207. Casadei Gardini A, Chiadini E, Faloppi L, Marisi G, Delmonte A, **Scartozzi M**, Loretelli C, Lucchesi A, Oboldi D, Dubini A, Frassinetti GL, Ulivi P. Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. *BMC Cancer.* 2016 Jul 7;16:429. doi: 10.1186/s12885-016-2463-2. PubMed PMID: 27388325; PubMed Central PMCID: PMC4937544.
 208. Faloppi L, Bianconi M, Memeo R, Casadei Gardini A, Giampieri R, Bittoni A, Andrikou K, Del Prete M, Cascinu S, **Scartozzi M**. Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. *Biomed Res Int.* 2016;2016:7196280. doi: 10.1155/2016/7196280. Review. PubMed PMID: 27314036; PubMed Central PMCID: PMC4903134.
 209. Pani F, Atzori F, Baghino G, Boi F, Ionta MT, Tanca L, **Scartozzi M**, Mariotti S. Hypothyroidism and Thyroid Autoimmunity as a Prognostic Biomarker of Better Response in Metastatic Cancer Long-Term Survivors Treated with Sunitinib. *Thyroid.* 2016 Sep;26(9):1336-7. doi: 10.1089/thy.2016.0159. PubMed PMID: 27267354.
 210. Puzzoni M, Silvestris N, Leone F, Giampieri R, Faloppi L, Demurtas L, Dell'Aquila E, Marino D, Brunetti O, Garattini SK, Ongaro E, Astara G, Orgiano L, Aprile G, Santini D, **Scartozzi M**. The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? *Target Oncol.* 2016 Oct;11(5):593-603. Review. PubMed PMID: 27184491.
 211. Madeddu C, Deidda M, Piras A, Cadeddu C, Demurtas L, Puzzoni M, Piscopo G, **Scartozzi M**, Mercurio G. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. *J Cardiovasc Med (Hagerstown).* 2016 May;17 Supp 1:S12-8. doi: 10.2459/JCM.0000000000000376. PubMed PMID: 27183520.
 212. Aprile G, Ferrari L, Cremolini C, Bergamo F, Fontanella C, Battaglin F, Rihawi K, Lonardi S, Loupakis F, Scartozzi M. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. *Expert Rev Clin Pharmacol.* 2016 Jul;9(7):877-85. doi:10.1080/17512433.2016.1182861. PubMed PMID: 27149032.
 213. Giampieri R, Salvatore L, Del Prete M, Prochilo T, D'Anzeo M, Loretelli C, Loupakis F, Aprile G, Maccaroni E, Andrikou K, Bianconi M, Bittoni A, Faloppi L, Demurtas L, Montironi R, Scarpelli M, Falcone A, Zaniboni A, **Scartozzi M (corr Author)**, Cascinu S. Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. *Sci Rep.* 2016 Apr 27;6:25195. doi:10.1038/srep25195. PubMed PMID: 27117754; PubMed Central PMCID: PMC4846860.
 214. Faloppi L, Del Prete M, Casadei Gardini A, Santini D, Silvestris N, Bianconi M, Giampieri R, Valgiusti M, Brunetti O, Bittoni A, Andrikou K, Lai E, Dessi A, Cascinu S, **Scartozzi M**. The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. *Sci Rep.* 2016 Apr 11;6:24136. doi: 10.1038/srep24136. PubMed PMID: 27063994; PubMed Central PMCID: PMC4827080.
 215. Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M, Lauletta G, Corbelli J, Valgiusti M, Fachetti F, Della Corte C, Neri LM, Tamberi S, Cascinu S, **Scartozzi M**, Amadori D, Nanni O, Tenti E, Ulivi P, Frassinetti GL. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. *Oncotarget.* 2016 May 10;7(19):27988-99. doi: 10.18632/oncotarget.8569. PubMed PMID: 27058899; PubMed Central PMCID: PMC5053704.
 216. Giampieri R, Caporale M, Pietrantonio F, De Braud F, Negri FV, Giuliani F, Pusceddu V, Demurtas L, Restivo A, Fontanella C, Aprile G, Cascinu S, **Scartozzi M**. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? *Crit Rev Oncol*

- Hematol. 2016 Apr;100:99-106. doi: 10.1016/j.critrevonc.2016.02.005. Review. PubMed PMID: 26907512.
217. Casadei Gardini A, Scarpi E, Marisi G, Foschi FG, Donati G, Giampalma E, Faloppi L, **Scartozzi M**, Silvestris N, Bisulli M, Corbelli J, Gardini A, La Barba G, Veneroni L, Tamberi S, Cascinu S, Frassinetti GL. Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. *Oncotarget*. 2016 Mar 22;7(12):15243-51. doi: 10.18632/oncotarget.7444. PubMed PMID: 26893366; PubMed Central PMCID: PMC4924783.
218. Giampieri R, Maccaroni E, Mandolesi A, Del Prete M, Andrikou K, Faloppi L, Bittoni A, Bianconi M, Scarpelli M, Bracci R, **Scartozzi M**, Cascinu S. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. *Gastric Cancer*. 2017 Jan;20(1):156-163. doi: 10.1007/s10120-016-0594-4. PubMed PMID:26796888.
219. Bittoni A, Del Prete M, **Scartozzi M**, Pistelli M, Giampieri R, Faloppi L, Bianconi M, Cascinu S. Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. *Springerplus*. 2015 Dec 1;4:743. doi: 10.1186/s40064-015-1545-y. eCollection 2015. PubMed PMID: 26693102; PubMed Central PMCID: PMC4666886.
220. Casadei Gardini A, Marisi G, Scarpi E, **Scartozzi M**, Faloppi L, Silvestris N, Masi G, Vivaldi C, Brunetti O, Tamberi S, Foschi FG, Tamburini E, Tenti E, Ricca Rosellini S, Ulivi P, Cascinu S, Nanni O, Frassinetti GL. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. *Expert Opin Pharmacother*. 2015 Dec;16(18):2719-25. doi: 10.1517/14656566.2015.1102887. Epub 2015 Oct 29. PubMed PMID: 26513009.
221. Maccaroni E, Bracci R, Giampieri R, Bianchi F, Belvederesi L, Brugiati C, Pagliaretta S, Del Prete M, **Scartozzi M**, Cascinu S. Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal? *Oncotarget*. 2015 Nov 17;6(36):38737-48. doi: 10.18632/oncotarget.5395. PubMed PMID: 26485756.
222. Faloppi L, Bianconi M, Giampieri R, Sobrero A, Labianca R, Ferrari D, Barni S, Aitini E, Zaniboni A, Boni C, Caprioni F, Mosconi S, Fanello S, Berardi R, Bittoni A, Andrikou K, Cinquini M, Torri V, **Scartozzi M**, Cascinu S; Italian Group for the Study of Digestive Tract Cancer (GISCAD). The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. *Oncotarget*. 2015 Oct 27;6(33):35087-94. doi: 10.18632/oncotarget.5197. PubMed PMID: 26397228.
223. Restivo A, Cocco IM, Casula G, Scintu F, Cabras F, **Scartozzi M**, Zorcolo L. Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer. *Br J Cancer*. 2015 Oct 20;113(8):1133-9. doi: 10.1038/bjc.2015.336. Epub 2015 Sep 15. PubMed PMID: 26372700; PubMed Central PMCID: PMC4647877.
224. Aprile G, Silvestris N, Antonuzzo L, **Scartozzi M**. Metastatic gastric cancer in the last two decades: goals achieved and future promises. *Future Oncol*. 2015 Sep 11. [Epub ahead of print] PubMed PMID: 26357981.
225. Aprile G, Rihawi K, **Scartozzi M**, Bordonaro R. Steps ahead in the treatment of advanced colorectal cancer: past, current and possible future scenarios. *Future Oncol*. 2015 Sep 11. [Epub ahead of print] PubMed PMID: 26357968.
226. Del Prete M, Giampieri R, Loupakis F, Prochilo T, Salvatore L, Faloppi L, Bianconi M, Bittoni A, Aprile G, Zaniboni A, Falcone A, **Scartozzi M (corr Author)**, Cascinu S. Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. *Oncotarget*. 2015 Oct 20;6(32):33982-92. doi: 10.18632/oncotarget.5053. PubMed PMID: 26334693.
227. Gnani A, Santini D, **Scartozzi M**, Russo A, Licchetta A, Palmieri V, Lupo L, Faloppi L, Palasciano G, Memeo V, Angarano G, Brunetti O, Guarini A, Pisconti S, Lorusso V, Silvestris N. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment.

- Is there a light at the end of the tunnel? *Expert Opin Ther Targets*. 2015 Dec;19(12):1623-35. Doi 10.1517/14728222.2015.1071354. Epub 2015 Jul 27. PubMed PMID: 26212068.
228. Giampieri R, **Scartozzi M**, Del Prete M, Faloppi L, Bianconi M, Ridolfi F, Cascinu S. Prognostic Value for Incidental Antihypertensive Therapy With β -Blockers in Metastatic Colorectal Cancer. *Medicine (Baltimore)*. 2015 Jun;94(24):e719. doi: 10.1097/MD.0000000000000719. PubMed PMID: 26091452.
229. Minardi D, **Scartozzi M**, Montesi L, Santoni M, Burattini L, Bianconi M, Lacetera V, Milanese G, Cascinu S, Muzzonigro G. Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. *Springerplus*. 2015 Jun 12;4:255. doi: 10.1186/s40064-015-1036-1. eCollection 2015. PubMed PMID: 26085975; PubMed Central PMCID: PMC4463949.
230. Bianconi M, Faloppi L, Del Prete M, Giampieri R, Bittoni A, Lopez-Beltran A, Scarpelli M, Cheng L, **Scartozzi M**, Cascinu S, Montironi R. Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward? *Anal Quant Cytopathol Histopathol*. 2015 Feb;37(1):3-13. PubMed PMID: 26072629.
231. Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, **Scartozzi M**. Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. *Onco Targets Ther*. 2015 May 22;8:1149-56. doi: 10.2147/OTT.S82624. eCollection 2015. Review. PubMed PMID: 26045669; PubMed Central PMCID: PMC4447178.
232. 5: Rihawi K, Giampieri R, **Scartozzi M**, Pusceddu V, Bonotto M, Fasola G, Cascinu S, Aprile G. Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. *Expert Opin Investig Drugs*. 2015 Jun 4:1-14. [Epub ahead of print] PubMed PMID: 26044119.
233. **Scartozzi M**, Giampieri R, Aprile G, Iacono D, Santini D, dell'Aquila E, Silvestris N, Gnoni A, Bonotto M, Puzzone M, Demurtas L, Cascinu S. The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. *Expert Rev Mol Diagn*. 2015 Aug;15(8):979-87. doi: 10.1586/14737159.2015.1047346. Epub 2015 May 15. PubMed PMID: 25975986.
234. Giampieri R, Mandolesi A, Abouelkhair KM, Loretelli C, Del Prete M, Faloppi L, Maristella B, Ibrahim EM, Scarpelli M, Cascinu S, **Scartozzi M**. Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. *J Transl Med*. 2015 May 7;13:140. doi: 10.1186/s12967-015-0501-5. PubMed PMID: 25943333; PubMed Central PMCID: PMC4424481.
235. Gnoni A, Silvestris N, Licchetta A, Santini D, **Scartozzi M**, Ria R, Pisconti S, Petrelli F, Vacca A, Lorusso V. Metronomic chemotherapy from rationale to clinical studies: A dream or reality? *Crit Rev Oncol Hematol*. 2015 Jul;95(1):46-61. doi: 10.1016/j.critrevonc.2015.01.008. Epub 2015 Jan 20. Review. PubMed PMID: 25656744.
236. Minardi D, Quaresima L, Santoni M, Bianconi M, **Scartozzi M**, Cascinu S, Muzzonigro G. Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature. *Curr Urol Rep*. 2015 Feb;16(2):3. doi: 10.1007/s11934-014-0478-2. PubMed PMID: 25627021.
237. Minardi D, Lucarini G, Santoni M, Mazzucchelli R, Burattini L, Conti A, Principi E, Bianconi M, **Scartozzi M**, Milanese G, Di Primio R, Montironi R, Cascinu S, Muzzonigro G. Survival in patients with clear cell renal cell carcinoma is predicted by HIF-1 α expression. *Anticancer Res*. 2015 Jan;35(1):433-8. PubMed PMID: 25550584.
238. Aprile G, Giampieri R, Bonotto M, Bittoni A, Ongaro E, Cardellino GG, Graziano F, Giuliani F, Fasola G, Cascinu S, **Scartozzi M**. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. *Expert Opin Investig Drugs*. 2014 May 7. [Epub ahead of print] PubMed PMID: 24806575.

239. Faloppi L, **Scartozzi M**, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R, Del Prete M, De Minicis S, Bitetto D, Loretelli C, D'Anzeo M, Benedetti A, Cascinu S. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. *BMC Cancer*. 2014 Feb 20;14(1):110. doi: 10.1186/1471-2407-14-110. PubMed PMID: 24552144; PubMed Central PMCID: PMC3930857.
240. **Scartozzi M**, Faloppi L, Svegliati Baroni G, Loretelli C, Piscaglia F, Iavarone M, Toniutto P, Fava G, De Minicis S, Mandolesi A, Bianconi M, Giampieri R, Granito A, Facchetti F, Bitetto D, Marinelli S, Venerandi L, Vavassori S, Gemini S, D'Errico A, Colombo M, Bolondi L, Bearzi I, Benedetti A, Cascinu S. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study. *Int J Cancer*. 2014 Feb 8. doi: 10.1002/ijc.28772. [Epub ahead of print] PubMed PMID: 24510746.
241. **Scartozzi M**, Giampieri R, Del Prete M, Faloppi L, Bianconi M, Vincenzi B, Tonini G, Santini D, Cascinu S. Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. *Expert Opin Pharmacother*. 2014 Jan;15(1):143-50. doi: 10.1517/14656566.2014.860964. Epub 2013 Nov 28. PubMed PMID: 24283747.
242. Orciani M, Lazzarini R, **Scartozzi M**, Bolletta E, Mattioli-Belmonte M, Scalise A, Di Benedetto G, Di Primio R. The response of breast cancer cells to mesenchymal stem cells: a possible role of inflammation by breast implants. *Plast Reconstr Surg*. 2013 Dec;132(6):899e-910e. doi: 10.1097/01.prs.0000434401.98939.60. PubMed PMID: 24281636.
243. Bittoni A, **Scartozzi M**, Giampieri R, Faloppi L, Bianconi M, Mandolesi A, Del Prete M, Pistelli M, Cecchini L, Bearzi I, Cascinu S. Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. *PLoS One*. 2013 Nov 12;8(11):e78544. doi: 10.1371/journal.pone.0078544. eCollection 2013. PubMed PMID: 24265697; PubMed Central PMCID: PMC3827058.
244. Minardi D, Lucarini G, Santoni M, Mazzucchelli R, Burattini L, Pistelli M, Bianconi M, Di Primio R, **Scartozzi M**, Montironi R, Cascinu S, Muzzonigro G. VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. *Anticancer Res*. 2013 Nov;33(11):5017-22. PubMed PMID: 24222145.
245. Negri FV, Azzoni C, Bottarelli L, Campanini N, Mandolesi A, Wotherspoon A, Cunningham D, **Scartozzi M**, Cascinu S, Tinelli C, Silini EM, Ardizzoni A. Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. *Anticancer Res*. 2013 Oct;33(10):4611-7. PubMed PMID: 24123038.
246. **Scartozzi M**, Giampieri R, Loretelli C, Bittoni A, Mandolesi A, Faloppi L, Bianconi M, Del Prete M, Andrikou K, Bearzi I, Cascinu S. Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. *Pharmacogenomics*. 2013 Dec;14(16):1991-8. doi: 10.2217/pgs.13.185. Epub 2013 Oct 3. PubMed PMID: 24090479.
247. Giampieri R, **Scartozzi M**, Loretelli C, Piva F, Mandolesi A, Lezoche G, Del Prete M, Bittoni A, Faloppi L, Bianconi M, Cecchini L, Guerrieri M, Bearzi I, Cascinu S. Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. *PLoS One*. 2013 Sep 4;8(9):e72843. doi: 10.1371/journal.pone.0072843. eCollection 2013. PubMed PMID: 24023782; PubMed Central PMCID: PMC3762853.
248. Giampieri R, **Scartozzi M**, Del Prete M, Maccaroni E, Bittoni A, Faloppi L, Bianconi M, Cecchini L, Cascinu S. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. *Crit Rev Oncol Hematol*. 2013 Nov;88(2):272-83. doi:10.1016/j.critrevonc.2013.05.008. Epub 2013 Jun 24. PubMed PMID: 23806981.
249. **Scartozzi M**, Giampieri R, Loretelli C, Mandolesi A, del Prete M, Biagetti S, Alfonsi S, Faloppi L, Bianconi M, Bittoni A, Bearzi I, Cascinu S. Role of $\beta 4$ integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. *Future Oncol*. 2013 Aug;9(8):1207-14. doi: 10.2217/fon.13.72. Epub 2013 Apr 26. PubMed PMID: 23617461.

250. **Scartozzi M**, Bianconi M, Faloppi L, Loretelli C, Bittoni A, Del Prete M, Giampieri R, Maccaroni E, Nicoletti S, Burattini L, Minardi D, Muzzonigro G, Montironi R, Cascinu S. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. *Br J Cancer*. 2013 Mar 19;108(5):1126-32. doi: 10.1038/bjc.2012.501. Epub 2012 Nov 29. PubMed PMID: 23511629; PubMed Central PMCID: PMC3619056.
251. Bittoni A, **Scartozzi M**, Giampieri R, Faloppi L, Maccaroni E, Del Prete M, Bianconi M, Cascinu S. The Tower of Babel of liver metastases from colorectal cancer: are we ready for one language? *Crit Rev Oncol Hematol*. 2013 Mar;85(3):332-41. doi: 10.1016/j.critrevonc.2012.08.005. Epub 2012 Sep 8. Review. PubMed PMID: 22964298.
252. Bianconi M, **Scartozzi M**, Faloppi L, Bittoni A, Maccaroni E, Giampieri R, Del Prete M, Burattini L, Cascinu S. Angiogenetic pathway as a therapeutic target in renal cell carcinoma. *Anal Quant Cytol Histol*. 2012 Feb;34(1):15-22. PubMed PMID: 22590815.
253. **Scartozzi M**, Loretelli C, Galizia E, Mandolesi A, Pistelli M, Bittoni A, Giampieri R, Faloppi L, Bianconi M, Prete MD, Bianchi F, Belvederesi L, Bearzi I, Cascinu S. Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients. *PLoS One*. 2012;7(7):e38192. Epub 2012 Jul 9. PubMed PMID: 22808003; PubMed Central PMCID: PMC3392267.
254. **Scartozzi M**, Giampieri R, Maccaroni E, Mandolesi A, Biagetti S, Alfonsi S, Giustini L, Loretelli C, Faloppi L, Bittoni A, Bianconi M, Del Prete M, Bearzi I, Cascinu S. Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. *J Transl Med*. 2012 Apr 10;10(1):71. [Epub ahead of print] PubMed PMID: 22490361.
255. **Scartozzi M**, Faloppi L, Bianconi M, Giampieri R, Maccaroni E, Bittoni A, Del Prete M, Loretelli C, Belvederesi L, Svegliati Baroni G, Cascinu S. The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management. *PLoS One*. 2012;7(3):e32653. Epub 2012 Mar 26. PubMed PMID: 22461886; PubMed Central PMCID: PMC3312882.
256. Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, **Scartozzi M**, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? *Ann Oncol*. 2012 Mar 5. [Epub ahead of print] PubMed PMID: 22396447.
257. **Scartozzi M**, Giampieri R, Maccaroni E, Del Prete M, Faloppi L, Bianconi M, Galizia E, Loretelli C, Belvederesi L, Bittoni A, Cascinu S. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. *Br J Cancer*. 2012 Feb 28;106(5):799-804. doi: 10.1038/bjc.2012.17. Epub 2012 Feb 7. PubMed PMID: 22315053; PubMed Central PMCID: PMC3305976.
258. **Scartozzi M**, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, Silva R, Zaniboni A, Biscotti T, Biagetti S, Galizia E, Loupakis F, Falcone A, Bearzi I, Cascinu S. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. *Ann Oncol*. 2011 Nov 23. [Epub ahead of print] PubMed PMID: 22112971.
259. Battelli N, Bittoni A, Pagliacci A, Zeponi L, **Scartozzi M**, Mariotti C, Cascinu S. Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. *Tumori*. 2011 Jul-Aug;97(4):449-53. doi: 10.1700/950.10396. PubMed PMID: 21989432.

260. Berardi R, Santinelli A, Brunelli A, Onofri A, Pierantoni C, **Scartozzi M**, Pisa E, Stramazzotti D, Mazzanti P, Zuccatosta L, Gasparini S, Sabbatini A, Cascinu S. Epidermal growth factor receptor status in stages of resected non-small cell lung cancer: implications for treatment with epidermal growth factor receptor inhibitors. *Anal Quant Cytol Histol*. 2011 Aug;33(4):196-204. PubMed PMID: 21980623.
261. **Scartozzi M**, Loretelli C, Berardi R, Pierantoni C, Silva RR, Mari D, Giampieri R, Faloppi L, Pistelli M, Maccaroni E, Bittoni A, Del Prete M, Galizia E, Cascinu S. Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. *Dig Liver Dis*. 2012 Jan;44(1):74-9. Epub 2011 Sep 3. PubMed PMID: 21893437.
262. Pistelli M, **Scartozzi M**, Bittoni A, Galizia E, Berardi R, Cascinu S. Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice. *Tumori*. 2011 May-Jun;97(3):275-9. doi: 10.1700/912.10021. PubMed PMID: 21789002.
263. **Scartozzi M**, Bearzi I, Mandolesi A, Giampieri R, Faloppi L, Galizia E, Loupakis F, Zaniboni A, Zorzi F, Biscotti T, Labianca R, Falcone A, Cascinu S. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. *Br J Cancer*. 2011 May 24;104(11):1786-90. Epub 2011 May 10. PubMed PMID: 21559018; PubMed CentralPMCID: PMC3111171.
264. Marmorale C, Stortoni P, Siquini W, **Scartozzi M**, Berardi R, Mandolesi A, Bearzi I, Fianchini A. Adenocarcinoma arising from ileoanal J-pouch mucosa: an announced event? *Inflamm Bowel Dis*. 2011 Jun;17(6):E57-8. doi: 10.1002/ibd.21711. Epub 2011 Apr 6. PubMed PMID: 21472828.
265. **Scartozzi M**, Bianconi M, Maccaroni E, Giampieri R, Del Prete M, Berardi R, Cascinu S. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. *Discov Med*. 2011 Feb;11(57):144-53. Review. PubMed PMID: 21356169.
266. **Scartozzi M**, Loretelli C, Berardi R, Pierantoni C, Silva RR, Mari D, Giampieri R, Faloppi L, Pistelli M, Maccaroni E, Bittoni A, Del Prete M, Galizia E, Cascinu S. Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. *Dig Liver Dis*. 2011 Sep 3. [Epub ahead of print] PubMed PMID: 21893437.
267. **Scartozzi M**, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S. 5-Fluorouracil pharmacogenomics: still rocking after all these years? *Pharmacogenomics*. 2011 Feb;12(2):251-65. Review. PubMed PMID: 21332317.
268. **Scartozzi M**, Mandolesi A, Giampieri R, Bittoni A, Pierantoni C, Zaniboni A, Galizia E, Giustini L, Silva RR, Bissoni R, Berardi R, Biscotti T, Biagetti S, Bearzi I, Cascinu S. The Role of HER-3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab. *Oncologist*. 2011;16(1):53-60. Epub 2011 Jan 6.
269. **Scartozzi M**, Baroni GS, Faloppi L, Paolo MD, Pierantoni C, Candelari R, Berardi R, Antognoli S, Mincarelli C, Risaliti A, Marmorale C, Antico E, Benedetti A, Cascinu S. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. *J Exp Clin Cancer Res*. 2010 Dec 15;29:164. PubMed PMID: 21159184.
270. Berardi R, Onofri A, Pistelli M, Maccaroni E, **Scartozzi M**, Pierantoni C, Cascinu S. Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. *Core Evid*. 2010 Oct 21;5:61-76. PubMed PMID: 21042543;
271. **Scartozzi M**, Loretelli C, Bearzi I, Mandolesi A, Galizia E, Onofri A, Pistelli M, Bittoni A, Berardi R, Cascinu S. Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis

- capability of gastric cancer cells in radically resected patients. *Ann Oncol.* 2010 Oct 6. [Epub ahead of print]
272. Cascinu S, Galizia E, Labianca R, Ferraro F, Pucci F, Silva RR, Luppi G, Beretta GD, Berardi R, **Scartozzi M**. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. *Cancer Chemother Pharmacol.* 2010 Sep 7.
 273. Faloppi L, **Scartozzi M**, Maccaroni E, Di Pietro Paolo M, Berardi R, Del Prete M, Cascinu S. Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-tailored therapeutic options. *Cancer Treat Rev.* 2010 Aug 25. [Epub ahead of print]
 274. **Scartozzi M**, Siquini W, Galizia E, Stortoni P, Marmorale C, Berardi R, Fianchini A, Cascinu S. The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis. *Dig Liver Dis.* 2011 Mar;43(3):194-8. Epub 2010 Aug 21.
 275. **Scartozzi M**, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S. Dalotuzumab, a recombinant humanized mAb targeted against IGF1R for the treatment of cancer. *Curr Opin Mol Ther.* 2010 Jun;12(3):361-71.
 276. Bittoni A, Maccaroni E, **Scartozzi M**, Berardi R, Cascinu S. Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. *Eur Rev Med Pharmacol Sci.* 2010 Apr;14(4):309-14.
 277. **Scartozzi M**, Pistelli M, Bittoni A, Giampieri R, Galizia E, Berardi R, Faloppi L, Del Prete M, Cascinu S. Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy. *Curr Oncol Rep.* 2010 May;12(3):175-85.
 278. Beretta GD, **Scartozzi M**, Tondulli L, Cascinu S. Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities? *J Clin Oncol.* 2010 Jun 1;28(16):e268-9; author reply e270. Epub 2010
 279. **Scartozzi M**, Mandolesi A, Giampieri R et al: Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. *Int J Cancer* 2010
 280. Berardi R, Maccaroni E, Onofri A, Giampieri R, Pistelli M, Bittoni A, **Scartozzi M**, Pierantoni C, Mandolesi A, Bearzi I, Cascinu S. Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. *Expert Opin Pharmacother.* 2009 Oct;10(15):2467-78.
 281. **Scartozzi M**, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, Berardi R, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. *BMC Cancer.* 2009 Aug 27;9:303. PubMed
 282. **Scartozzi M**, Mazzanti P, Giampieri R, Berardi R, Galizia E, Gasparini S, Zuccatosta L, Cascinu S. Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable? *Lung Cancer.* 2009 Aug 5. [Epub ahead of print]
 283. Berardi R, Maccaroni E, Onofri A, Giampieri R, Bittoni A, Pistelli M, **Scartozzi M**, Pierantoni C, Bianconi M, Cascinu S. Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. *Expert Opin Pharmacother.* 2009 Oct;10(14):2245-58. PubMed PMID: 19640208.
 284. **Scartozzi M**, Bittoni A, Pistelli M, Galizia E, Berardi R, Giampieri R, Faloppi L, Cascinu S. Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. *Cancer Treat Rev.* 2009 Aug;35(5):451-62.

285. Loupakis F, Pollina L, Stasi I, Ruzzo A, **Scartozzi M**, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. *J Clin Oncol*. 2009 Jun 1;27(16):2622-9. Epub 2009 Apr 27. PubMed PMID: 19398573.
286. Berardi R, Mantello G, **Scartozzi M**, Del Prete S, Luppi G, Martinelli R, Fumagalli M, Grillo-Ruggieri F, Bearzi I, Mandolesi A, Marmorale C, Cascinu S. Locally Advanced Rectal Cancer Patients Receiving Radio-chemotherapy: A Novel Clinical-Pathologic Score Correlates with Global Outcome. *Int J Radiat Oncol Biol Phys*. 2009 Apr 20. [Epub ahead of print] PubMed PMID: 19386440.
287. **Scartozzi M**, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. *Ann Oncol*. 2009 Feb;20(2):227-30. Epub 2008 Oct 7. PubMed PMID: 18842611; PubMed Central PMCID PMC2640179
288. Pierantoni C, Pagliacci A, **Scartozzi M**, Berardi R, Bianconi M, Cascinu S. Pancreatic cancer: Progress in cancer therapy. *Crit Rev Oncol Hematol*. 2008 Mar 18 [Epub ahead of print]
289. Amati M, Tomasetti M, **Scartozzi M**, Mariotti L, Alleva R, Pignotti E, Borghi B, Valentino M, Governa M, Neuzil J, Santarelli L. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. *Cancer Epidemiol Biomarkers Prev*. 2008 Jan;17(1):163-70.
290. Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, Cammilluzzi E, Crinò L, De Marinis F, Di Pietro FA, Grossi F, Innocenzi D, Micali G, Piantedosi FV, **Scartozzi M**. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting. *Crit Rev Oncol Hematol*. 2007 Dec 20; [Epub ahead of print]
291. Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di Costanzo F, Dapretto E, Tonini G, Pierantoni C, Artale S, Rota S, Floriani I, **Scartozzi M**, Zaniboni A; Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. *Lancet Oncol*. 2008 Jan;9(1):39-44.
292. Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, **Scartozzi M**, Crocicchio F, Mari E, Ardizzoni A. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. *Br J Cancer*. 2008 Jan 15;98(1):71-6. Epub 2007 Dec 4.
293. Cascinu S, **Scartozzi M**, Carbonari G, Pierantoni C, Verdecchia L, Mariani C, Squadroni M, Antognoli S, Silva RR, Giampieri R, Berardi R. COX-2 and NF-kB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. *Am J Clin Oncol*. 2007 Oct;30(5):526-30.
294. **Scartozzi M**, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A, Catalano V, Quadri A, Zorzi F, Berardi R, Biscotti T, Labianca R, Falcone A, Cascinu S. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. *J Clin Oncol*. 2007 Sep 1;25(25):3930-5
295. Cascinu S, Zaniboni A, **Scartozzi M**, Meriggi F. Molecular biology for stage II colorectal cancer: the jury is still out. *J Clin Oncol*. 2007 Jul 1;25(19):2861;
296. **Scartozzi M**, Bearzi I, Berardi R, Mandolesi A, Pierantoni C, Cascinu S. Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. *Br J Cancer*. 2007 Jul 2;97(1):92-7

297. **Scartozzi M**, Galizia E, Verdecchia L, Berardi R, Antognoli S, Chiorrini S, Cascinu S. Chemotherapy for advanced gastric cancer: across the years for a standard of care. *Expert Opin Pharmacother*. 2007 Apr;8(6):797-808
298. **Scartozzi M**, Falcone A, Pucci F, Braconi C, Pierantoni C, Cavanna L, Franciosi V, Berardi R, Beretta G, Masi G, Allegrini G, Zaniboni A, Labianca R, Cascinu S. Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. *Tumori*. 2006 Sep-Oct;92(5):384-8.
299. Berardi R, Braconi C, Mantello G, **Scartozzi M**, Del Prete S, Luppi G, Martinelli R, Fumagalli M, Valeri G, Bearzi I, Marmovale C, Grillo-Ruggieri F, Cascinu S. Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. *Ann Oncol*. 2006 Nov;17(11):1661-4. Epub 2006 Sep 12.
300. Berardi R, **Scartozzi M**, Freddari F, Squadroni M, Santinelli A, Bearzi I, Fabris G, Cascinu S. Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review. *Cancer Treat Rev*. 2006 Aug;32(5):333-47.
301. **Scartozzi M**, Galizia E, Verdecchia L, Berardi R, Graziano F, Catalano V, Giordani P, Mari D, Silva RR, Marmorale C, Zingaretti C, Cascinu S. Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. *Br J Cancer*. 2006 Aug 21;95(4):445-9.
302. Cascinu S, Verdecchia L, Valeri N, Berardi R, **Scartozzi M**. New target therapies in advanced pancreatic cancer. *Ann Oncol*. 2006 May;17 Suppl 5:v148-v152.
303. **Scartozzi M**, Franciosi V, Campanini N, Benedetti G, Barbieri F, Rossi G, Berardi R, Camisa R, Silva RR, Santinelli A, Ardizzoni A, Crino L, Rindi G, Cascinu S. Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. *Lung Cancer*. 2006 Jul;53(1):103-9.
304. **Scartozzi M**, Pierantoni C, Berardi R, Antognoli S, Bearzi I, Cascinu S. Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer. *Anal Quant Cytol Histol*. 2006 Apr;28(2):61-8.
305. **Scartozzi M**, Pierantoni C, Berardi R, Squadroni M, Cascinu S. Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice. *Expert Opin Ther Targets*. 2006 Apr;10(2):281-7.
306. Berardi R, Grilli G, Romagnoli E, Saladino T, Freddari F, Tamburrano T, Galizia E, Carbonari G, Mariani C, Braconi C, Pierantoni C, Battelli N, **Scartozzi M**, Cascinu S. *Clin Ter*. 2005 Nov-Dec;156(6):281-8.
307. Berardi R, Saladino T, Mari D, Silva RR, **Scartozzi M**, Verdecchia L, Onori A, Cascinu S. Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy. *Tumori*. 2005 Nov-Dec;91(6):463-6.
308. **Scartozzi M**, Sobrero A, Gasparini G, Berardi R, Catalano V, Graziano F, Barni S, Zaniboni A, Beretta GD, Labianca R, Cascinu S; Italian Group for the Study of Digestive Tract Cancer. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. *Oncology*. 2005;68(2-3):212-6. Epub 2005 Jul 7.
309. Berardi R, Brunelli A, Tamburrano T, Verdecchia L, Onofri A, Zuccatosta L, Gasparini S, Santinelli A, **Scartozzi M**, Valeri G, Giovagnoni A, Giuseppetti GM, Fabris G, Marmorale C, Fianchini A, Cascinu S. Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. *Lung Cancer*. 2005 Sep;49(3):371-6.
310. **Scartozzi M**, Berardi R, Pierantoni C, Cascinu S. Pre-operative treatment modalities in gastric cancer patients. *Ann Oncol*. 2005 May;16(suppl_4):iv106-iv109.

311. Graziano F, Ruzzo A, Santini D, Humar B, Tonini G, Catalano V, Berardi R, Pizzagalli F, Arduini F, Bearzi I, **Scartozzi M**, Cascinu S, Testa E, Ficarelli R, Magnani M. Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. *J Clin Oncol*. 2005 Apr 1;23(10):2339-45.
312. **Scartozzi M**, Galizia E, Graziano F, Catalano V, Berardi R, Baldelli AM, Testa E, Mari D, Silva RR, Cascinu S. Over-DI dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. *Br J Cancer*. 2005 Mar 28;92(6):1051-4.
313. Berardi R, Verdecchia L, **Scartozzi M**, Cascinu S. New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocols. *JOP*. 2005 Jan 13;6(1 Suppl):118-21.
314. **Scartozzi M**, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. *J Clin Oncol*. 2004 Dec 1;22(23):4772-8. Erratum in: *J Clin Oncol*. 2005 Jan 1;23(1):248.
315. Galizia E, Berardi R, **Scartozzi M**, Cascinu S. A cost-benefit analysis of chemotherapy for gastric cancer. *Expert Opin Pharmacother*. 2004 Oct;5(10):2109-14.
316. Graziano F, Mandolesi A, Ruzzo A, Bearzi I, Testa E, Arduini F, Silva R, Mureto P, Mari D, Berardi R, **Scartozzi M**, Lai V, Cascinu S, Magnani M. Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. *Tumour Biol*. 2004 May-Jun;25(3):106-10.
317. **Scartozzi M**, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. *Cancer Treat Rev*. 2004 Aug;30(5):451-9.
318. Cascinu S, **Scartozzi M**, Labianca R, Catalano V, Silva RR, Barni S, Zaniboni A, D'Angelo A, Salvagni S, Martignoni G, Beretta GD, Graziano F, Berardi R, Franciosi V; Italian Group for the Study of Digestive Tract Cancer (GISCAD). High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). *Br J Cancer*. 2004 Apr 19;90(8):1521-5.
319. Freddari F, Berardi R, **Scartozzi M**, Cascinu S. [Non-small cell lung carcinoma: pathology, biology and prognosis] *Suppl Tumori*. 2004 Mar-Apr;3(2):S3-4.
320. Berardi R, **Scartozzi M**, Romagnoli E, Antognoli S, Cascinu S. Gastric cancer treatment: a systematic review. *Oncol Rep*. 2004 Apr;11(4):911-6.
321. Graziano F, Arduini F, Ruzzo A, Mandolesi A, Bearzi I, Silva R, Mureto P, Testa E, Mari D, Magnani M, **Scartozzi M**, Cascinu S. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. *Ann Oncol*. 2004 Mar;15(3):489-92.
322. Berardi R, Porfiri E, **Scartozzi M**, Lippe P, Silva RR, Nacciarriti D, Menichetti ET, Tummarello D, Carle F, Piga A, Cellerino R. Elderly patients with advanced non-small cell lung cancer. A phase II study with weekly cisplatin and gemcitabine. *Oncology*. 2003;65(3):198-203.
323. Berardi R, **Scartozzi M**, Galizia E, Cascinu S. Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literature. *Suppl Tumori*. 2003 Sep-Oct;2(5):S45-7.
324. Berardi R, Latini L, Santinelli A, Herber N, Baldassarre S, **Scartozzi M**, Cellerino R. Mucocele-like tumour of the breast. *J Exp Clin Cancer Res*. 2003 Jun;22(2):329-32.

325. **Scartozzi M**, De Nictolis M, Galizia E, Carassai P, Bianchi F, Berardi R, Gesuita R, Piga A, Cellerino R, Porfiri E. Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. *Eur J Cancer*. 2003 May;39(8):1144-9.
326. **Scartozzi M**, Bianchi F, Rosati S, Galizia E, Antolini A, Loretelli C, Piga A, Bearzi I, Cellerino R, Porfiri E. Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression. *J Clin Oncol*. 2002 Mar 1;20(5):1203-8.
327. Massacesi C, Bascioni R, Cellerino R, **Scartozzi M**, Bracci R, Alessandrini P, Antognoli S, Ciavattini A, De Nictolis M, Piga A. Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer. *J Exp Clin Cancer Res*. 2000 Mar;19(1):13-6.
328. Cascinu S, Catalano V, Baldelli AM, **Scartozzi M**, Battelli N, Graziano F, Cellerino R. Locoregional treatments of unresectable liver metastases from colorectal cancer. *Cancer Treat Rev*. 1998 Feb;24(1):3-14.
329. Cascinu S, Catalano V, **Scartozzi M**, Baldelli AM, Cellerino R. Liver metastases from colorectal cancer. *Ann Oncol*. 1997 Apr;8(4):393-9.

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV.

Dichiaro di aver preso visione dell'informativa resa ai sensi del Capo III – Diritti dell'interessato, ai sensi del Regolamento (EU) 2016/679 del 27 aprile 2016 (GDPR) e autorizzazione al trattamento dei dati personali forniti ai fini della presente procedura.

Questo documento è redatto sotto forma di autocertificazione ai sensi degli articoli 46 e 47 del DPR n 445/2000 con consapevolezza delle conseguenze derivanti da dichiarazioni mendaci ai sensi dell'art 76 del DPR n 445/2000.

sincerely

Cagliari (Italy) February 24th, 2025

prof Mario Scartozzi

AUTORIZZAZIONE AL TRATTAMENTO DEI DATI PERSONALI (ARTT. 13 E 23 DEL D.LGS. 196/2003)

Il sottoscritto Prof Mario Scartozzi

AUTORIZZA

ai sensi e per gli effetti degli artt. 13 e 23 del D.Lgs. n. 196/2003, con la sottoscrizione del presente modulo, il proprio consenso al trattamento dei dati personali forniti.

DATA 24 Febbraio 2025 Firma Prof Mario Scartozzi